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Scientific Environment  
The PhD project is funded at the Faculty of Medicine and Dentistry, University of 
Bergen. By collaboration with the KG Jebsen Center for Influenza vaccine research, I 
was solely involved at the Influenza Centre in Bergen. The whole scientific expertise 
and the knowledge I have learnt during my Ph.D. at the Influenza Centre were guided 
and directly supervised by the Professor Rebecca Jane Cox Brokstad, University of 
Bergen (UiB). The project managed by Professor Cox and she was my main 
supervisor, while Professor Bjarne Bogen from University of Oslo acted as my co-
supervisor. The PhD project was conducted for four years (2014-2018) and was part 
of a larger clinical trial studying the immune responses after live attenuated influenza 
vaccine conducted in 2012-2014 as collaborative work between the Influenza Centre, 
the Paediatric clinical trial unit and the Ear Nose and Throat (ENT) departments at 
the Haukeland University Hospital (HUH). All the necessary experiments and the 
present work in the dissertation were carried out at the laboratory of the Influenza 
Centre, Department of the Clinical Science (K2). The mandatory courses were 
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According to the WHO (World Health Organization), one billion peoples are infected 
annually of whom three to five millions become severely ill and 250-500 000 deaths 
worldwide (He, Wang et al. 2013) although the latest research reported 291-645 000 
deaths each year (4.0-8.8 per one hundred thousand individuals). Occasional 
pandemics cause even higher rates of mortality. Controlling influenza infection is a 
frontline problem for human health. Vaccination is considered the best strategy for 
reducing influenza infection. However, antigenic drift of influenza requires updating 
of the vaccine each year to match the circulating virus strains to provide optimal 
vaccine efficacy. Currently, two different types of vaccines are in clinical use; 
trivalent inactivated vaccines (TIV) and trivalent live attenuated influenza vaccines 
(LAIV). Quadrivalent LAIV is also approved and used in some countries. The 
majority of currently approved seasonal influenza vaccines are TIV, delivered 
intramuscularly or deep subcutaneously, which can further be subdivided as split-
virion vaccines and subunit vaccine based on their formulations (Toback, Levin et al. 
2012). On the other hand, only one LAIV is licensed in the USA and Europe for 
specific at risk populations. The vaccine compromises live attenuated influenza 
viruses produced by reverse genetics that can replicate efficiently (Coelingh, Luke et 
al. 2014). Moreover, live attenuated, cold-adaptive, trivalent influenza virus vaccine 
is administered intranasally representing a convenient, safe and effective approach for 
the prevention of influenza in children (Belshe, Mendelman et al. 1998). However, 
strain-matched vaccines often lag behind the antigenic changes in the virus and in the 
event of a pandemic, there is a time lag of at least six months before the vaccine is 
available (Epstein and Price 2010). Thus, the concept of ‘universal influenza vaccine’ 
is under discussion to reduce all influenza A virus infections by providing broad 
cross-reactive (heterosubtypic) immunity. Several studies have shown that LAIV can 
boost virus-specific cytotoxic T lymphocytes, as well as mucosal and serum 
antibodies and induce broad cross-protection against heterologous human influenza A 
viruses (He, Wang et al. 2013). Although the integrated approach provides evidence 
of cross-protective immunity, the underlying mechanism is poorly understood.  
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This research project therefore mainly addressed some of the fundamental research 
questions of how LAIV provides protective immunity. We have been shown a 
significant elevated neutralizing antibody response after LAIV in children measured 
by haemagglutinin inhibition (HI) assay. Further we dissected haemagglutinin (HA) 
to head and stalk antibody responses, we observed in children that LAIV significantly 
elicited H3 head specific antibodies. H1 stalk specific antibodies were also increased 
but not significantly. In contrast in adults, LAIV did not boost antibody responses 
(Paper I). 
 
We found that H1N1pdm09 virus specific humoral immunity was not boosted in 
general, although NAI responses were elevated in children. CD4 T-cell responses in 
blood were also induced against H1N1 vaccine strain. Influenza specific IFN-γ 
responses increased in children as well (Paper II). The influenza B strain specific 
IFN-γ responses increased both locally (TMNC) and systemically (PBMC). LAIV 
resulted in a significant increase in CD8+ T-cell responses post-vaccination in the 
tonsils suggesting LAIV is able to induce cross-reactive local CD8+ T-cells in the 
upper respiratory tract (Paper III). In contrast to the observation in USA, our overall 
results illustrated in this thesis correspond to the response found in other European 
countries, like UK and Finland. Our finding suggest that the H1N1 vaccine strain in 
LAIV may have protected children through NAI and T cellular responses, suggesting 
support for continued use of live attenuated influenza vaccine for children. The 
multifaceted immune response following LAIV immunization in children suggests 






Research at the Influenza Centre, Bergen has for many years focused on better 
understanding of influenza virus and vaccines that help to address the control of 
future influenza infection. The head of the centre, Professor Rebecca Jane Cox 
Brokstad has a long-standing interest in influenza research. Professor Cox and her 
collaborators have conducted clinical trials registry and built biobanks from 
vaccinated children and adults, which provides a unique possibility to investigate live 
attenuated influenza vaccine (LAIV) specific immunity in both groups. By combining 
this unique biobank with the expertise on clinical vaccinology, immunology and 
gold-standard serological methodology residing within the group of Professor Cox, I 
tried to address the mechanisms of immunity induced by LAIV. The project 
integrates advanced functional vaccine studies with analysis of Norwegian children 
and adult samples, and involves local, national, and international collaboration. As 
such, I believe this project meets many of the research objectives of the KG Jebsen 
Centre for Influenza research, with translational and clinical research on immunology 
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1.1 Influenza A Virus 
Influenza virus is a member of the Orthomyxoviridae virus family and is a single 
stranded negative sense RNA virus with eight gene segments. Four types of influenza 
virus have been identified (A, B C and D). Types A and B are commonly circulating 
in humans and causes disease, whereas, type C is associated with mild discomfort 
mainly in children. Influenza type D virus has recently been isolated from pigs and 
cattle [1]. Influenza A viruses infects several mammals and bird species and animals, 
many of them are domesticated like pigs, horses, ducks, chicken and turkey. The 
natural reservoir for influenza A is believed to be waterfowl, aquatic birds and 
occasionally the virus is also identified and isolated in wild aquatic mammals like 
seals and whales. Influenza B and C viruses are mainly human pathogens [2, 3]. The 
influenza A genome contains eight RNA segments coding for at least 17 proteins 
including 2 surface glycoproteins, HA (Haemagglutinin) and NA (Neuraminidase). 
Classification of influenza A viruses into subtypes is based on these two surface 
glycoproteins. Currently, there are 18 known subtypes of HA  (H1-H18) and 11 
subtypes of NA (N1-N11) and allowing different subtypes (H/N combinations) e.g. 
H1N1, H5N1 or H3N2 [1, 4]. 
1.1.1 Viral Structure 
Influenza virus is mainly pleomorphic but also found spherical in structure, but 
elongated filamentous forms can also be observed. New progeny virus measures 80-
120 nm in diameter. The virion is enveloped with a lipid bilayer containing surface 
glycoproteins HA and NA and the ion channel (M2). Influenza A virus (IAV) has 
eight segments of negative sense RNA genome which range between 890-2341 base 
pairs in length [5]. Each RNA segment encodes at least one essential protein. The 
RNA encodes segments as for the following genes Polymerase basic 2 (PB2), 
Polymerase basic 1 (PB1), Polymerase acid (PA), HA, Nucleoprotein (NP), NA, 
Introduction 
 2 
Matrix (M) and Non-Structural (NS) [6]. A schematic diagram of influenza A virus is 
illustrated below in Figure 1. 
 
Influenza A virus 
 
 
Figure 1. Illustration of Influenza A virus structure showing the important surface 
glycoproteins, the location of the others virus proteins and the 8 negative sense RNA 
segments. 
1.1.2 Haemagglutinin 
Haemagglutinin (HA) is the major surface glycoprotein of influenza A virus. The HA 
is a trimer composed of three monomeric HA proteins The HA is produced as an 
immature polypeptide chain or precursor (HA0), which is cleaved by the host’s 
proteases to produce two distinct subunits; the head (HA1) and the stalk (HA2) The 
globular head (HA1) contains the receptor binding site and the main antigenic sites 
and is prone to mutation enabling the virus to escape the hosts immune response. This 
process of accumulated mutations introduces changes in the main epitopes is called 
‘antigenic drift’. The HA2 together with N-and C-terminal HA1 residues form the 
K.A. Brokstad © 
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most conserved transmembrane stalk domain. The stalk is functionally responsible 
for fusion of viral and endosomal membranes.  The function of the HA is to facilitate 
binding of the virus to the host cell’s sialic acids (SA). Sialic acids are widely 
distributed on many different cells in the respiratory tract, such as the epithelial cells, 
dendritic cells and alveolar macrophages. The binding affinity of the virus depends 
upon the type of sialic acids and their associated oligosaccharides, with human 
influenza viruses preferentially binding α2,6 linked SA [6]. 
1.1.3 Neuraminidase 
The second surface glycoprotein of influenza virus A is neuraminidase; a 
homotetrameric structure with a mushroom shape and highly conserved active sites. 
The NA protein is coded by the 6th segment of RNA. It comprises 470 amino acid 
residues and several domains; the globular head domain that is connected to stalk 
domain rooted in the viral membrane by a hydrophobic transmembrane region. The 
NA stalk can vary in length depending on adaption to the host, but the enzymatic 
active site and the calcium binding sites lies on the NA head and potentially stabilizes 
the NA structure at low pH in the presence of calcium ion [7-9]. The function of NA 
is well characterized and involved in different phases of the virus infection life cycle. 
Neuraminidase is mainly involved in releasing progeny virions by cleaving sialic 
acids from the cell surface and facilitating the virus release from the infected cells 
[10]. Importantly, NA is also involved in virus entry and actively plays a role in 
binding the virus to the host cell membrane [11]. NA cleaves sialic acid from the 
respiratory mucine, releasing the virus and therefore helping the virus to reach the 
target cells [10]. Interestingly, in mucus NA facilitate the cleavage of the α-ketosidic 
linkage between the terminal sialic acid and neighbouring sugar residue to facilitate 
virus in reaching the target cells, whereas HA binds to the sialic acid residues to 
promote the virus entry. The receptor destroying function of NA, and its 
complementary activity to HA of binding to the sialic acid receptor shows the 
importance of their co-operation and/or competition for infection [8]. 
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1.1.4 Internal Virus Proteins 
Nucleoprotein (NP) and the polymerase complex proteins (PA, PB1 and PB2) are the 
internal proteins that play important roles in viral transcription and replication. The 
polymerase complex is a heterotrimer formed by PB1 with the PA on one side and by 
the N-terminal domain of PB2 on the other side [12]. The nucleoprotein encapsidates 
each viral RNA (vRNA) segment and support viral RNA synthesis. Viral mRNA 
transcription from vRNA is initiated by the primers and also generated through PA 
dependent cap snatching of host mRNAs [13]. The PB2 generally binds to the capped 
RNAs [14] and PB1 performs the actual RNA synthesis [15-17]. The polymerase 
complex lacks proof reading capability, which consequently results in a relative high 
gene mutation rate, contributing to antigenic drift and is a major determinant of viral 
virulence and host adaptation. However, the molecular structure of the polymerase 
complex has been elucidated and future interpretation of their function by inhibition 
and/ or blocking could improve antiviral strategies [18].   
1.1.5 Matrix And Non-structural Proteins 
Matrix proteins, M1 and M2, are encoded from a single gene segment 7 (M). M1 is 
the structural component with lipid binding properties and interacts with the lipid 
membrane of influenza virus. The main function of M1 is export of the vRNPs to the 
cytosol from the nucleus which occurs at the later stages of influenza infection [19]. 
Moreover, the post-translational cellular phosphorylation is necessary to prevent re-
uptake of the vRNPs to the nucleus by M1 [20]. M2 is a transmembrane protein, 
which act as an ion channel that makes a pore in the viral envelope. M2 plays a 
crucial role in the early stages of viral replication by promoting an acidic 
environment to facilitate viral uncoating [21]. The M2 also functions at the later stage 
of infection, M2 protein is important in viral budding and allows release of new 
virions for further infection [22].  
The two non-structural internal influenza proteins are NS1 and NS2, which are 
alternative splicing products encoded from the smallest gene (segment 8) of the viral 
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genome. In brief, NS1 is a pleiotropic virulence factor that interacts with multiple 
cellular components. It plays an important role in interfering with the type I 
interferons produced by the host system to repress innate antiviral mechanisms and 
thereby inhibit host IFN responses [23, 24]. NS1 can interfere with the host cell 
mRNA processing unit to repress nuclear export of cellular mRNA [25] and interfere 
with mRNA translation to favour viral protein translation [26]. NS2 was re-named as 
nuclear export protein or NEP recently. NEP is involved in helping M1 to export 
vRNP from the nucleus to the cytoplasm [27]. Both NEP and more specifically NS1 
are considered as potential target for the development of antiviral drugs. 
1.1.6 Influenza A Virus Molecular Structure And Replication Cycle 
The spherical influenza A virus with its genome segments inside is covered by an 
outer host cell derived lipid bilayer membrane containing the glycoproteins HA and 
NA; at a ratio of one NA to four HAs, and also the transmembrane ion channel M2. 
The HA head, with its receptor binding domain, attaches to N-acetylneuraminic acid 
of the host respiratory epithelium cells through α2,6 linkage in humans. Many bird 
viruses has high affinity to the α2,3 linkages, while pig adapted virus may binds both 
α2,3 and α2,6 sialic acids. NA also helps the virus to reach the target cell by 
enhancing cleavage of terminal sialic acid from its neighbouring sugar residue [28]. 
These molecular properties of surface glycoproteins facilitate virus attachment to the 
host cells and initiate the virus entry through clathrin mediated endocytosis process. 
The transmembrane M2 ion channel plays an important role in virus entry thereafter. 
The M2 ion channel, found only in influenza viruses, is responsible for triggering the 
change to the acidic environment in endosomal vesicles by pumping the hydrogen 
ions inside the virus particle from the endosome and lowering the pH. The acidic 
change facilitates a conformational change in the HA structure catalysed by the host 
protease (serine) to expose the fusion peptide. The fusion peptide in the HA stalk is 
cleaved and allows the triple α-helix bundle to extended leading to fusion of the viral 
and endosomal membranes. This fusion enables the virus uncoating allowing release 
of the viral genome segments into the host cell cytoplasm.  Once the viral genome is 
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released into the cytoplasm, transport signal or nuclear localization signals (NLSs) 
translocate and direct the vRNP to the nucleus (reviewed in [29, 30]).  
Most negative sense RNA viruse replication occurs in the cytoplasm, but influenza 
virus is different (Figure 2). Influenza virus performs its replication cycle in the 
nucleus of the host cell by interacting with host cell nuclear machinery [31]. 
Influenza viral genome transcription is initiated by the viral RNA dependent RNA 
polymerase complex and through viral mRNA synthesis. Newly transcribed mRNAs 
are then transported to the cytoplasm for translation. The replication is also carried 
out by producing a positive strand complimentary RNA (cRNA) from viral genome 
to use as an intermediate template, which is then transcribed to vRNA. Newly 
replicated vRNA coated in nucleoprotein and the RNA polymerase, are then directed 
to the infected cell membrane for assembly. The newly formed virions are then 
released by budding process with help from NA.  
 
Figure 2. Illustration of influenza A virus life cycle, 1) free virion, 2-3) attachment and 
endosomal uptake, 4) genome release, 5) viral replication to vRNA and mRNA, 6) synthesis 
of viral proteins and glycoproteins, 7) assemble and 8) release. 
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1.2 Natural Infection by Influenza Virus And Burden of Disease  
1.2.1 Influenza Virus History: Epidemics And Pandemics 
Influenza associated illness have been observed and reported for many centuries, 
although the causative virus was not identified until the 1930s [32], first in pigs and 
later in human [33]. The established reservoir of most subtypes of influenza A viruses 
are aquatic birds, except H17 and H18 which are found in bats, although a wide range 
of species are also susceptible such as pigs, horses and humans. Phylogenetic analysis 
suggests that the known mammalian influenza A viruses are mostly derived from the 
avian reservoir [34]. In man, the virus is able to infect all year round globally, but the 
large wave of infection is often seen in the winter months in the Northern and 
Southern hemispheres. Worldwide evolutionary studies illustrate distinct patterns of 
influenza infection with different circulating strains. Therefore the southern and 
northern hemispheres have significant differences in dominant prevailing influenza 
strains [35]. The frequent migration of aquatic bird is often responsible for 
transmission of influenza both intra- and inter-species including zoonotic 
transmission to man. The high density of human population, open yard poultry 
production (hens, ducks etc.), live-poultry or animal market provides the ideal 
condition for influenza virus natural reassortment. The transmission of influenza 
between avian species has increased particularly in Asia, which also increases 
possible zoonosis. Poultry farms can be a source of highly pathogenic influenza virus, 
which can infect poultry workers and potentially spread to others [36]. Pigs are also 
considered as the ‘mixing vessel’ containing both receptors for avian (sialic acids 
with α-2,3-galactose linkage) and human (α-2,6-galactose linkage) viruses. 
The potential of influenza viruses is due to the antigenic variation in the two major 
surface glycoprotein of the virus; the HA and NA. The variation occurs due to the 
point mutations (including insertion, substitution and deletions) in HA and NA genes, 
in a process known as ‘antigenic drift’. As influenza virus lacks proof reading 
machinery this allows the genetic variation to be transcribed during the viral 
replication cycle. If an antigenic change in the surface glycoproteins occurs that 
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allows the virus strain to escape neutralization by existing immunity against the 
previously infected strains. 
Epidemic; Epidemics are the major wave of seasonal infection, which occur due to 
‘antigenic drift’ of the circulated strain. Due to the genetic alterations in the viral 
genome, the novel virus is often closely related to previously circulating strains, 
resulting in sporadic localized outbreaks or epidemics. Amino acid changes in the 
antigenic sites in HA and NA allow the virus to escape existing immune defences. 
Current epidemics are mostly caused by influenza A H3N2 strain, Influenza A H1N1 
or the influenza B virus.  
Pandemic; A novel virus can arise as a result of reassortment of circulating and 
animal viruses or multiple influenza infections in a host at the same time. This novel 
virus can then spread globally if the population is immunologically naïve and this is 
referred to as ‘antigenic shift’. This causes a pandemic, which is a large-scale global 
outbreak with a novel virus that overcomes a weak community resistance. The result 
is associated with global transmission with high morbidity and high mortality. 
Several pandemic outbreaks have occurred with millions of deaths. The 1918 
pandemic was caused by the H1N1 subtype, resulting in over 20 million deaths and is 
also known as Spanish flu. Thereafter, pandemics occurred in 1957 (Asian pandemic, 
H2N2 subtype), and 1968 (Hong Kong pandemic, H3N2 subtype), in 1977 the re-
emergence of the H1N1 subtype (Russian pandemic) and very recently 2009 
pandemic (Swine flu). 
1.2.2 Global Flu Burden  
The Spanish flu in 1918 was the deadliest influenza pandemic known to man, and is 
thought to have infected approximately one-third of the world’s population, at that 
time 500 million people and with at least 20-50 million death estimated [37]. As a 
consequence, the World Health Organisations (WHO) influenza surveillance system 
was adopted in 1947 and has for more than 80 years continuously measured the 
burden of influenza around the world. The annual global burden depends upon the 
circulating virus types and subtypes for influenza A, status of the immunity in the 
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population and vaccination coverage, alongside the vaccine match to circulating 
strains. Annually influenza infection related illness, absenteeism, hospitalization and 
deaths have great socio-economic impact. Seasonal influenza infection is mostly 
associated with affecting elderly and people in high-risk groups, whereas, pandemic 
influenza is often associated with high mortality rates across the population 
particularly in the young and elderly. Although the elderly did not suffer high 
mortalities rates during the swine 2009 pandemic, probably due to cross-reactive 
antibody from previous older H1N1 strains [38]. Recent studies demonstrated the 
actual number of influenza death was underestimated in the 2009 pandemic. The 
WHO reported approximately 250-500 thousands of deaths annually from seasonal 
influenza infection, which is 3.8-7.7 individuals per one hundred thousand people. 
The latest research reported that seasonal influenza causes 291-645 thousands of 
deaths, which is 4.0-8.8 per one hundred thousand individuals [39]. In the USA alone, 
the Centers for Disease Control and Prevention (CDC) estimates 9.2 -35.6 million 
illnesses with influenza symptoms and 140-710 thousands of hospitalization, with the 
mortality reported as between 12-56 thousands each year since 2010 [40]. In children, 
the influenza A subtypes (H1N1 and H3N2) and Influenza B cause higher prevalence 
rates of cough, wheezing, vomiting and convulsions compare to the children with 
other respiratory infections [41]. The influenza related illness causes a heavy global 
burden especially due to high rates of illness in the high-risk groups (Table 1), like 
young children, elderly people and pregnant women. Importantly, influenza-like 
illness has great socio-economic impact on children and their families due to need for 
healthcare and absence from day care or the work place. Thus, the direct effect on 







Table 1: High risk groups recommended for annual vaccination against 
seasonal influenza 
Norwegian recommendation (NIPH) International recommendation (WHO) 
Pregnant women  
• After 12 weeks of pregnancy 
(2nd 3rd trimester) and during 1st 
trimester in some cases 
Pregnant women 
• Highest priority for increased 
risk of severe disease and fatal 
outcome due to influenza, 
which causes stillbirth, 
neonatal death, pre-term 
delivery and low birth weight 
Children and adults with 
• Diabetes mellitus, type 1 and 2  
• Chronic respiratory disease  
• Chronic cardiovascular disease  
• Chronic liver failure  
• Chronic renal failure  
• Chronic neurological disease or 
injury  
• Immunodeficiency disorders  
• Severe obesity (BMI over 40)  
• Other severe or chronic illness 
evaluated on an individual 
basis by a doctor 
Children aged < 6 months 
• Cannot be vaccinated but can 
be protected specifically 
through vaccination of their 
mothers during pregnancy 
 
Children < 2 years old 
• Should be target group 
 
Children 2-5 years old 
• The group have high burden of 
disease. When available, LAIV 
immunization showed higher 
protection and broader 
protection 
 
Person with specific chronic disease 
 
Elderly > 65 years Elderly individuals ≥ 65 years of age 
• Highest risk of influenza 
associated mortality 
Subjects in nursing homes and 
sheltered accommodation  
 
Others 
• Health professional with patient 
contact 
• Household contacts of 
immunosuppressed patients 
• Pig farmers who have regular 
contact with live pigs 
Others 
• Heath-care workers  
• International travellers  
* NIPH stands for Norwegian Institute of Public Health and the information provided [45] 




1.3 Immunity Against Influenza A Virus (IAV) Infection 
Infection with influenza virus occurs generally in the upper respiratory tract through 
the oral or nasal cavity with brief encounter of the mucous layer, which covers the 
epithelial cells. The mucosal immune system is therefore the first line of defence 
against influenza infection. Mucosal immunity has specialized defence mechanism 
providing protection against invasion of potential mucosal pathogens, like influenza 
virus [47]. Some highly pathogenic influenza virus successfully can invade the 
mucous layer and attach to the epithelial cells, where the front line defence is initiated 
[48].  
1.3.1 Innate And Adaptive Immunity 
The innate immune system provides [49] immunity by recognition of the pathogen 
associated molecular patterns (PAMPs) of IAVs by pathogen recognition receptors 
(PRRs). Retinoic acid-inducible gene-I (RIG-I) and toll-like receptor (TLR) are PRRs 
which cause activation of hundreds of genes that also are known as ISGs or IFN-
stimulating genes, responsible for induction of the innate immune defence (Figure 3). 
PRRs can distinguish self from non-self-molecules within the infected cells and also 
cause the secretion of type I IFN, pro-inflammatory cytokines, eicosanoids and 
chemokines. By playing distinct roles, inflammatory cytokines and eicosanoids 
induce the early symptoms of infection in host but also inform the adaptive immune 
system about the influenza infection. At the same time, chemokines are produced and 
secreted at the site of infection, which leads to recruitment of others immune cells 
including natural killer (NK) cells to facilitate phagocytic viral clearance. Together 
with IFNs-I producing macrophages, DCs and pDCs, phagocytic cells of the innate 
immune system provide protection by clearing virus-infected cells through complex 
mechanisms. Based on the location, macrophages are the one of the earliest cells that 
responds to the influenza virus. The importance of macrophages against influenza 
infection is very critical but essential for protection. They internalize the virus and 
enhance lysosomal degradation, remove the degraded debris of apoptotic cells. And 
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most importantly, macrophages help to induce adaptive immune response by antigen 
presentation to the naïve T-cells.   
 
 
Figure 3. Activation of innate immune system against influenza A virus (IAV) infection. 
Influenza virus recognized by PRRs PAMP/DAMP and initiates signal transduction and a 
cellular pathway, reaching transcriptional factors in the machinery regulating antiviral genes. 
 
If a virus penetrates the innate immune defence barrier, infection can successfully be 
established. Thus, the ultimate clearance of the virus or virus-infected cell is 
dependent on the adaptive immunity. Adaptive immunity comprises both B- and T-
cells that play important roles against IAV infection. B-cells produce antibodies to 
combat infection and reduce viral replication. Antibodies directed to the HA head 
region can neutralize the virus preventing infection of the host cell. Antibodies can 
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also mediate other effector functions to kill influenza virus infected cells, known as 
antibody dependent cellular cytotoxicity (ADCC) [50-52]. 
CD8+ T-cells are activated from T-cell zone enriched with migrated DCs and 
differentiated into cytotoxic T-lymphocytes (CTLs). Through the infection signal, 
CTLs initiates signals to produce cytokines and immunomodulatory molecules to 
restrict influenza virus replication. Cytotoxic T-lymphocytes are therefore involved in 
reducing viral shedding by killing the infected cells [53]. CD4+ T-cells are another 
major type of immune cells that play key roles in the adaptive immune system. CD4+ 
T-cells are also known as T-helper (Th) cells and can differentiate into Th1, Th2, 
Th17 and regulatory T-cells among others [54]. In response to influenza virus 
infection, CD4+ T-cells become activated, differentiate and predominantly produce 
co-stimulatory molecules, cytokines to regulates T-cell response [55]. They are 
importantly involved in regulation of T-cell mediated B-cell response [56] and 
sometimes promotes killer cells to combat influenza virus [57]. Tfh cells are another 
specialized subsets of CD4+ T-cells exclusively found in lymphoid tissue and 
necessary for germinal centre formation in secondary lymphoid organs (SLOs). 
Germinal centre B-cells proliferate rapidly [58] and produce high affinity antibodies 
with great diversification and thus provide immune response often induced by 
immunization against influenza [59]. Tfh and FDC (follicular dendritic cell) cells also 
regulate the process to produce antibody secreting plasma cells and memory B-cells 
[60]. 
1.3.2 Humoral Immunity  
Humoral Immunity is the immunological responses provided by B-cell and by 
secreted antibodies. In influenza studies, the haemagglutination inhibitory (HI) 
antibody titre ≥ 40 has been used as a correlate of protection after infection or 
vaccination, and has been widely used for vaccine licensing for decades. B-cells are 
originating from the bone marrow [61]. The naïve, but mature B-cells expresses 
surface IgD antibodies along with IgM when circulates in the blood and lymphoid 
tissue. After antigen recognition, the B-cells migrate to T-cell rich area of lymphoid 
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tissue. Here the B-cells become activated by T-helper and Follicular T-helper cells, 
and they can proliferate and differentiate into antibody secreting plasma cells (ASC) 
and memory B-cells [62]. Upon re-exposure to antigen, secondary immune responses 
are initiated found by mainly memory B cells. While the primary immune response 
often are dominated by IgM, the secondary immune response shows signs of isotype 
switching, producing additional IgG, IgA and IgE antibodies. IgM is secreted as a 
pentameric antibody, but often have low affinity and avidity in contrasts with the 
higher affinity antibodies expressed by memory B-cells [63].  
Antibody-secreting plasma cells can be either short-lived or long-lived. They produce 
antibodies, which are strain specific and can be detected in the blood within 5-7 days 
of infection or vaccination depending on previous priming [64, 65]. IgA and IgG 
antibodies play important roles in influenza immunity. IgA antibodies provide the 
initial immune defence at the portal of viral entry; the respiratory mucosa, whereas 
IgG provides systemic protection against influenza virus infection [66, 67]. MBC in 
comparison, activate and differentiate into plasma cells when activated by an antigen 






modified from https://doi.org/10.1111/imr.12640 
Figure 4. Schematic illustration of how influenza virus infections lead to HA head/stalk 
specific B-cells activation, differentiation, proliferation and memory B-cell generation. A, 
Antibodies to immunodominant viral epitopes are marked in red (anti-haemagglutinin (HA) 
head domain), and antibodies towards conserved viral epitopes are marked in blue (anti-HA 
stalk domain). B, Illustration shows the recruitment of broadly reactive GC B-cells into the 
memory compartment mediated by T-cells help. Low affinity broadly reactive GC B-cells 
are more prone to be recruited into memory B-cell compartment.  
This strategy is exploited in priming and booster strategies for influenza vaccines 
[70]. Interestingly, MBC circulates from bone marrow to the periphery and the 
lymphoid organs for many years and may be for life-time. 
1.3.3 Cellular Immunity 
Cellular immunity is the effector function of both CD4+ and CD8+ T-cells. Antigen 
presenting cells (APCs) such as dendritic cells (DC) present antigenic peptide 
fragments bound to the major histocompability complex (MHC). T-cells require the 
antigen to be processed and presented by either MHC-I on circulating T-cells or 
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MHC-II on APCs before antigen recognition. In addition to antigen recognition, 
naïve T-cells also need stimulus from DC to become activated. The progenitor T-cells 
produced in the bone marrow are transported to the thymus to be matured along with 
the complex process of T-cell receptor (TCR) genes and diversified membrane 
marker expression. Proliferation and differentiation occurs to generate functionally 
distinct subpopulations mainly CD4+ and CD8+ T-cells. CD4+ T-cells are principle 
component of immune regulation [71] that become activated by recognising the 
antigenic peptide bound and expressed with co-stimulatory molecules with the MHC 
class II. Importantly, APCs (DC) can also present peptides to the CD8+ T-cells via 
MHC class I producing cytotoxic CD8+ T-cells, which are important in viral 
clearance. Activated T-cells are thereafter regulated by the production of different 
cytokines that also co-ordinate the T-cells clonal expansion and differentiation into 
both effector and memory cells.   
CD4+ T-cells plays key role in influenza prevention through the effector functions, 
which are involved in viral clearance either by directly killing infected cells or 
helping other cell types including B-cell stimulation and cytotoxic CD8+ T-cell 
activation. Activated B-cells produce antibodies, whereas macrophages destroy the 
ingested microbes upon activation. The important feature of the naive CD4+ T-cells 
is that they differentiate into different subsets upon interaction with APCs and 
regulate cellular immunity with distinct functions of the subtypes based on the 
infection environment, types of APCs and co-stimulatory molecules through specific 
cytokine production [72]. Naive CD4+ TCR coupled with CD3 initiate activation 
through antigen-MHC II complex that induces the downstream signalling pathway.  
Consequently, naive cells proliferate and differentiate into specific effector cells. 
Thus major subsets are the Th1 and Th2 cells. Both Th1 and Th2 cells are 
differentiated from naive CD4+ T-cells upon IL-12 and IFN-γ secretion [73], 
whereas, IL-4 and IL-2 are critical for Th2 differentiation [74]. The signalling 
pathway for Th1 differentiation starts with large amounts of IL-12 production from 
APCs, which in turn induces NK-cells to produce IFN-γ [75].  Th1 cells mainly 
secrets IFN-γ and IL-2, but also TNF- α, and are essentially involved in elimination 
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of intracellular pathogen. IFN-γ in particular is involved in activation of macrophages 
and microglial cells; the mononuclear phagocytes that enhanced phagocytic activity 
[76]. TNF−α potentially accelerates apoptosis and thereby acts as an 
immunosuppressive agent. One study reported increased TNF-α activation after 
influenza infection by NA which is thought to be involved in host response to 
mediate apoptosis [77]. The most potent cytokine produced by Th1 cells is IL-2 that 
promotes effector CD8+ T-cells for cytotoxic action [78]. IL-2 is an important growth 
factor that plays a role in T-cell growth but also increases the production of CD8+ 
memory T-cells. Thus by ensuring sufficient production of memory cells that 
circulate in the blood, lymphoid organs or periphery, IL-2 facilitates more rapid and 
strong secondary immune responses after antigen priming [79]. Interestingly, thymus 
derived regulatory T-cells need IL-2 to survive and thus plays a major role in immune 
suppression upon Treg activation [80]. Th2 cells are characteristically distinguished 
by their cytokine production of IL-4, IL-5, IL-10 and IL-13. Among them, the 
important function of IL-4 is to promote B-cells to IgE switching and secretion in the 
mucous against infection inflammation [81]. IL-10 causes inhibition of innate 
immune cells, as well as Th1 cells leading to maintenance of homeostasis after 
clearance of infection [82]. 
Recent studies have also identified others subtypes of differentiated CD4+ T-cells 
besides the classical Th1 and Th2, including Th17, Tfh, iTreg, Tr1, Th3, Th22 and 
with very recently Th9. The orchestration of naive CD4+ T-cells differentiation is 
illustrated below in Figure 5, involving direct and indirect cellular immunity after 




Figure 5. The naïve CD4+ T-cells differentiation into subtypes, which are characterized by 
the cytokines secreted. 
 
Th17 CD4+ T-cells have been found to be increased after intranasal influenza 
vaccination in mice and contributed to increased morbidity rather than viral clearance 
[83]. Interestingly, in hospitalized patients infected with severe pandemic H1N1 high 
level of Th17 mediators were found [84]. Follicular T-helper cell subsets of CD4+ T-
cells have been studied in recent years in influenza immunity as they have a role in 
promoting B-cell responses upon infection. CXCR5+CD4+T (Tfh) differentiate from 
CSCR5-CCR7+CD4+ naïve cells and play significant role in producing long-lived 
memory B-cells in the germinal centre. Based on the cytokine environment, Tfh-cells 
are also grouped into Tfh1, Tfh2 and Tfh10 with distinct functions. IFN-γ secretion 
by Tfh1 promotes IgG2, whereas Tfh2 produce IgG1 and IgE with the help of IL-4. 
Most importantly, Tfh10 facilitates mucosal defence against infection by IgA 
production upon IL-10 secretion [85].  
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CD8+ T-cells or CTLs (cytotoxic T-lymphocytes) mediate their function in clearing 
influenza-infected cells by two distinct pathways; cell lysis and apoptosis. Activated 
CD8+ T-cells primarily detect infected influenza cells by their TCR receptor and 
cause direct cytotoxic lysis by the Fas-dependent pathway or by perforins [86]. 
Secondly, clearance of virus-infected cells occurs through secretion of different 
cytokines [87, 88].  
1.3.4 Target Immune response by Live Attenuated Influenza Vaccine (LAIV) 
Live attenuated influenza virus is strain with very low pathogenicity and replication 
ability and can be used as vaccine, administered as nasal spray at the upper 
respiratory tract. Similar to the natural infection, LAIV induce multifaceted immune 
responses including plasma cells to produce both neutralizing and non-neutralizing 
antibodies. Importantly, LAIV can elicit cellular immunity (CD4+ and CD8+ T-cells) 
in children [89, 90]. LAIV mimics natural influenza infection, also induces broad 
cellular response and shown protection in animals against heterosubtypic influenza 
strains [91-93].  
Cell mediated immune protection against influenza by boosting CD8+ T-cells and 
CD4+ T-cells after LAIV immunization has been shown. And thus proved the 
concept of LAIV that the vaccine has potential impact on universal influenza vaccine 
development [94, 95]. Priming, pre-existing immunity and age plays important roles 
in the immunogenicity of LAIV. LAIV boosts T-cell responses in children that 
correlate with protection. The evidence clearly suggests that effector CD8+ T-cells 
cannot prevent infection but play crucial roles in reducing disease severity by killing 
and elimination of the virus infected cells to clear the infection. Effector CD8+ T-
cells also facilitates viral clearance by recruiting both innate and others adaptive 
immune cells through secretion of anti-viral cytokines and chemokines. Recovery 
from highly pathogenic influenza A H7N9 virus is associated with memory CD8+ T-
cell response that provided protection [96]. Influenza specific memory CD8+ T-cells 
were found as a correlate of protection against the pandemic influenza in the absence 
of cross-reactive neutralizing antibodies [95]. 
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Memory T-cells after LAIV immunization also showed robust induction of cellular 
immunity that causes reduction of the viral shedding although the underline 
mechanism has not been fully explained yet [97]. A key feature of memory T-cells is 
of cross-protection. Immediately after the viral clearance, the majority of effector 
plasma cells undergo apoptosis but a few remain in circulation as long-lived memory 
T-cells [98]. Upon recognition of a similar infection, memory cells initiate a rapid but 
massive clonal expansion and differentiate into the secondary effector T-cells to 
robustly clear the infection. Based on their functionality, memory T-cells are also 
grouped into effector memory T-cells and central memory T-cells. The central 
memory T-cells in the secondary lymphoid organ do function after meeting presented 
antigenic peptides and act more rapidly. They are activated T-cells that sit dormant in 
its position with low metabolic activity and wait to be reactivated. Upon reactivation, 
the memory T-cells become quickly active and can go directly into action. The 
effector memory cells are functionally like newly stimulated effector T-cells in the 
blood and non-lymphoid tissue [99]. The non-circulating tissue-resident memory T-
cells subset (RM) has also been recently characterized and provides the greatest 
protection against influenza infection [100]. RMT-cells enter into the tissue during 
their effector function phase and last until they recognize the antigenic peptides after 
selective expression of CD69 and CD103 [101, 102]. It is believed that resident-
memory T-cells protect against influenza at the mucosal site but both CD4+ and 
CD8+ RMT-cells are increased in the lungs of humans after recovery and may be a 
correlate of protection against influenza virus infection [100-104]. 
LAIV boosts memory B-cells responses in children as well and robustly induced 
antibodies to closely related influenza strains. Thus, B-cell mediated humoral 
immunity plays a crucial role to develop protective immunity against influenza 
infection through the activation of the cellular compartment by the help of different 
cytokines and chemokines production. Therefore, increased knowledge on LAIV 
studies will have great implications in future vaccine development.  
The conserved HA stalk specific immunity after LAIV vaccination is thought to be 
more heterosubtypic, which can provide cross-protection [105-107]. Several studies 
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demonstrated that stalk antibodies also recruit non-neutralizing antibodies to mediate 
cytotoxic destruction of infected cells, such as recruitment of NK-cells facilitates 
ADCC [51]. Therefore, the HA stalk is also considered as a potential target for future 
vaccine development [108-110]. Therefore, elucidation of the specificity of the stalk 
epitopes B-cells and T-cells and investigation of their function as well in downstream 
signalling will have the great importance. Furthermore, HLA or human leukocyte 
antigen complex encoding the MHC class-I or MHC class-II is crucial in antigenic 
peptide recognition. The HLA typing that customizes the epitopes (antigenic 
fragment) specificity often found to increase CD8+ and CD4+ T-cell responses and 
provide cross-protection [111, 112]. The approach can cover the large human 
population and could be useful for development of future vaccine development [113]. 
1.4 Availble Diagnostic tools, Preventive measures and Treatment of 
Influenza 
Diagnosis of influenza virus infection is often critical from a clinical perspective 
[114, 115]. The symptoms of influenza are associated with fever, muscle aches, 
headache, dry cough, sore throat, nasal congestion and runny nose that often provide 
discomfort to the infected individual and share clinical symptoms with others 
respiratory diseases including adenovirus, pneumoniae and respiratory syncytial 
viruses. General influenza infection associated discomfort resolves within a week and 
most people do not require medical assistance but hospitalization may be required 
based on the disease severity. Therefore, accurate and timely diagnosis of 
hospitalized influenza patients is important for initiation of antiviral treatment [116, 
117]. To date, several tests have been developed and are widely used for diagnosis of 
influenza virus infection, requiring respiratory specimen collection and antigen 
detection or nucleic acid amplification (NAA).  
After collection of respiratory specimens, influenza virus can be detected by the rapid 
tests, like PCR/Q-PCR, PCR ligation. Nucleic acid amplification test (NAA) by 
reverse transcription polymerase chain reaction (RT-PCR) is considered as the gold 
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standard for use in hospital or clinical environment due to the higher sensitivity. 
Moreover, influenza virus RNA can be stable for detection for several days by RT-
PCR regardless of sample collection, transport and processing time [114]. Virus 
activation assay is also used as non-rapid test. If the above mentioned diagnosis 
results are negative or unavailable, serology can be used to confirm influenza 
infection [118]. The common serology assays are, haemagglutination inhibition assay 
(HI), micro-neutralization assay (MN), complement fixation, enzyme-linked 
immunosorbant assay (ELISA) and enzyme-linked lectin assay (ELLA), which can 
be used for measuring both neutralizing and non-neutralizing antibodies [2]. 
Prevention is the primary measure to control influenza and always considered as 
more effective than treatment. Prophylaxis is recommended for preventing influenza 
infection and its severe complications, with annual vaccination recommended for 
high-risk groups. Although, vaccination rates have increased worldwide the vaccine 
coverage still needs to be improved to reach the 75% vaccination rate recommended 
by the WHO [119]. Particularly underdeveloped and developing countries have poor 
access and consequently poor influenza vaccine coverage rates [120]. These countries 
are particularly hard hit when a new pandemic emerges. The animal reservoir 
represents a considerable threat for the emergence of a new pandemic virus. Since, 
the emergence of the influenza A H7N9 virus in March 2013, China has experienced 
sixth zoonotic waves with a total of 1567 laboratory-confirmed human cases reported 
including 615 deaths so far [121, 122]. Vaccination is the most effective means to 
limit the influenza infection, and the severity of influenza associated morbidity and 
mortality. Although, antigenic mismatch between a vaccine virus strain and the 
circulatory strain in a year could potentially cause the lower vaccine efficacy 
nevertheless influenza vaccine is still cost effective. As we experienced during the 
2009 pandemic influenza virus infection, a period of at least six months is required 
before vaccine is available. For this reason preventive Mitigation strategies like, NPIs 
(Non-pharmaceutical Interventions) are now recommended when vaccines are not yet 
available [123, 124]. These include frequent handwashing, good cough hygiene, 
isolation of infected patients and use of face masks to reduce influenza viral 
transmission [125, 126]. Influenza virus transmits in humans mainly through air 
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droplets released by coughing, sneezing or talking with a sick individual. 
Transmission can be direct or indirect and the virus can be transmitted to healthy 
individuals up to six feet away [127]. The kindergarten and school children are 
considered as the main transmitters of influenza virus causing infection in their 
siblings and family. Healthcare workers in the front-line health care facilities have an 
increased risk of infection from flu patients. The overall economic burden from 
influenza and its associated complications is frequently under estimated due to the 
lack of public awareness or due to ignorance. NPIs limit the spread of highly 
contagious influenza virus and reduced the flu burden in a society [128]. 
1.4.1 Influenza Treatment by Vaccination  
Through antigenic drift and shift, the influenza virus is capable of escaping the 
immune system and widely infects humans resulting increased morbidity and 
mortality [129]. Having elevated anti-influenza antibodies do have an effect on 
protection and infection severity. Certain group in the “risk groups” population has 
been identical as more vulnerable to influenza infection, e.g. people aged ≥ 65 years. 
Influenza vaccination has been recommended for many years for the risk groups in 
order to reduce mortality and morbidity [130]. Reduction of virus spread through 
vaccination of school age children can reduces the spread in the community. 
Influenza vaccination is therefore the only global prophylaxis measure available. 
Although, some antiviral drugs are commercially available to treat influenza infected 
individuals. 
The first isolation of influenza virus in 1933 by Wilson Smith and his colleagues 
opened up the door to the production of influenza vaccines [131]. The first 
inactivated monovalent influenza vaccine was crudely purified from inactivated 
whole virus in 1942. In 1945, bivalent influenza vaccine containing one influenza A 
and one B strain was first licensed for use for civilians [132]. Later in 1970s, trivalent 
influenza vaccine containing two influenza A strains and one B strain were 
recommended for seasonal vaccination by World Health Organisation (WHO) [133]. 
In 2012 the U.S. Food and Drug Administration approved the quadrivalent live 
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attenuated influenza vaccine formulated as nasal spray containing two influenza A 
and two influenza B strains [134]. The European medicine agency also approved 
quadrivalent LAIV vaccine in 2013 to use in Europe [135]. Subsequently, a number 
of manufactures have had their quadrivalent IIVs licensed. 
Chemical inactivation of the whole virus was the first method of development of 
inactivated influenza vaccine (IIV). Live attenuated influenza vaccine is generated 
through genetic reassortment from the master donor virus (MDV). The stable but 
attenuated and cold-adapted MDV is used in the reverse genetics system with the 
surface glycoproteins from the wild-type strain to produce the master virus strain 
(MVS). Most commercial vaccines are produced by propagating the viruses in 
fertilized hen’s egg. Further preparation can vary, giving whole inactivated virus, 
split virus or subunit virus vaccine. Other varieties of vaccine can be produced in 
insect cells or recombinantly. In recent years, the recombinant flu vaccine has been 
licensed expressing the HA protein of the circulating strains by cloning into 
baculovirus vectors [136]. Some viruses need strains are genetically enhanced to 
provide certain immunological property, or give better growth yield or lower 
morbidity. 
The inactivated vaccines are all standardized by the amount of HA, and 
predominantly HA specific antibodies are induced. On the other hand, LAIV vaccine 
contains live attenuated viruses that may replicate and induce a multifaceted immune 
response. IIV is more effective in adults, whereas the LAIV provided better 





Figure 6. Commonly used vaccine types. 
 
1.4.2 Antiviral Drugs 
Two major viral antigens are targets of current antiviral drugs for influenza treatment. 
The transmembrane protein, M2-ion channel inhibitors were the first antiviral 
introduced and used in treatment of influenza patients up to 1999 [140]. Amantadine 
and rimantadine are the approved M2-ion channel inhibitor that inhibit influenza A 
viruses [141]. The adamantanes, M2 inhibitors function by interfering with viral 
endocytosis and release of viral RNA into the host cytoplasm that consequently 
inhibits the viral replication [142, 143]. The first M2-ion channel blocker amantadine 
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was initially approved to treat influenza A/H2N2 virus, and later for all strains. 
Rimantadine, the structural analogue of the amantadine, was approved for use against 
a variety of influenza A strains. In contrast to the amantadine, rimantadine has more 
antiviral specificity and is extensively metabolized. However, both of these antiviral 
drugs have been shown to shorten the duration and the severity of influenza A 
infection when taken within one to two days of developing symptoms. Although, they 
cannot be used against influenza B strain due to the lack of M2 protein. The major 
disadvantage of the ion channel inhibitors is they rapidly acquire resistance, 
particularly in the influenza A H3N2 virus [142] and cannot be used due to high 
levels of resistance in currently circulating viruses. Moreover, the adamantanes can 
have an adverse effect on the central nervous system although the risk is lower with 
rimantadine [144]. 
NA inhibitors (NAI) were first licensed for influenza treatment in 1999 and were the 
first structural-based drug designed. Over sixty years of scientific studies resulted in 
the achievement of the development of NA inhibitor; oseltamivir.  Since then, two 
more NA inhibitors known as peramivir and zanamivir have also been approved by 
FDA for treatment of circulating influenza viruses and also recommended by CDC as 
antiviral drugs for hospitalized severely ill patients [145]. NAIs block the release of 
progeny influenza virus from the infected host cell and thus restrict the spread of new 
virus infection to neighbouring host cells. Neuraminidase functions at the phase of 
releasing of progeny virus in the replication cycle, thereby NAIs are most effective at 
the peak of the influenza virus replication, generally between 24-72 hours of illness. 
These NAIs are capable of inhibiting influenza B and all Influenza A subtypes, 
therefore can be used against all influenza strains including both epidemic and 
pandemic viruses [146]. Some adverse effects have been observed after NAIs. 
Zanamivir is inhaled and may cause bronchospasms and decreased pulmonary 
functions, but is otherwise well tolerated [147]. Interestingly, some side effects of 
oseltamivir have also been reported upon administration such as nausea, vomiting and 
abdominal pain [148, 149]. A major negative impact has been reported after 
oseltamivir treatment in adults with renal impairment [150]. However, neuraminidase 
inhibitors rarely acquire result in development of resistance against any of the 
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influenza strains. To overcome the seasonal flu burden and the occasional pandemic 
catastrophe, several antiviral drugs are being developed. Internal proteins inhibitors 
are also targeted for the new drug development, like the newly approved baloxavir 
carboxyl, the potent PA inhibitor [151]. 
1.4.3 Others Prophylaxis 
With the moderate effectiveness of current influenza vaccines there is a need for next 
generation influenza vaccines to induce broad and long lasting immunity. Antibodies 
found against the conserved epitopes of the HA provide heterosubtypic and cross-
reactive immunity. Broadly cross-reactive monoclonal antibodies against the 
conserved HA stalk domain could be a new treatment or prophylactic measure when 
a new influenza virus strain emerged. Furthermore, generation of stalk based vaccines 
could be a novel approach. 
1.5 Influenza vaccines  
Licensed vaccines are available against seasonal or pandemic influenza to protect 
against epidemic strains or a new pandemic strain, respectively. Seasonal influenza 
vaccines combat the annual challenge in every season; and are updated twice a year. 
The composition of seasonal vaccines is recommended based on geographically 
dominant strains for the northern and southern hemispheres. Despite only providing 
moderate protection, vaccination is still the most important and cost-effective means 
to protect against influenza infection. The target groups for vaccination are people 
with an increased risk of severe influenza infection, such as those with chronic 
disease in all age groups, the elderly, pregnant women, health care workers and 
farmers working closely with swine and avian species. In the USA, CDC 
recommends annual influenza vaccination for the whole population from the age of 6 
months old [152]. The WHO has set pregnant women as the highest priority for 
vaccination and high priority for children between 6 to 59 months old, elderly people 
over 50 years of age, individuals with specific chronic medical conditions and health-
care workers in every season [153]. Influenza vaccination also have some 
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contraindications including people with severe allergy to egg proteins, but they can 
also be vaccinated with recombinant protein or cell culture produced vaccines 
therefore embryonated hens egg are not the substrate for the vaccine production. 
Influenza vaccines are also not recommended to children under the age of 6 months 
due to their immature immune system.  
1.5.1 Available Vaccines  
Since the historical development of first inactivated vaccine in 1945, the vaccine 
composition has evolved based on the circulating strains being isolated. Originally 
the vaccine was monovalent to protect against the circulating influenza A virus, then 
bivalent vaccines were developed for both influenza A and B strains. Later in 1970s, 
trivalent influenza vaccines were introduced, when completely new influenza A 
H1N1 strain with different HA and NA emerged [154]. In 2013, the quadrivalent 
seasonal vaccine consisting of two influenza B strains were recommended by WHO 
due to co-circulation of the two lineages B/Victoria and B/Yamagata. Today, the 
vaccine is mainly produced by propagation in embryonated hens eggs, even though, 
some inactivated vaccine production using MDCK cell culture. 
There are currently two types of approved influenza vaccines, inactivated influenza 
vaccine or IIV and live attenuated influenza vaccine or LAIV. The first recombinant 
influenza vaccine (RIV) is trivalent and approved by the FDA in January 2013 that 
used recombinant DNA technology to produce recombinant HA. Flublok RIV (Sanofi 
Pasteur) is now available as quadrivalent RIV vaccine in the 2018-2019 seasons in 
USA.  
1.5.2 Inactivated Influenza Vaccine (IIV) Vs. Live Attenuated Influenza Vaccine 
(LAIV) 
Several trivalent and quadrivalent IIVs are available on the market for 2018-19 
seasons. Quadrivalent IIVs includes Fluzone (Sanofi Pasteur), Flucelvax and Afluria 
(Seqires), Fluarix (GlaxoSmithKline) and FluLaval (ID Biomedical Corp. of 
Quebec). The available trivalent IIVs are Afluria and Fluad from Seqirus and Fluzone 
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from Sanofi Pasteur. The inactivated vaccine viruses is propagated in the allantoic 
fluid of embryonated hen’s eggs, virus is concentrated and purified before 
inactivation by beta-priolactone or formaldehyde or by detergent disruption for spilt 
or subunit vaccines. IIV can be formulated as whole virion or as split virus or subunit 
(contains HA and NA). The route of administration is either by deep subcutaneous 
(SC) or intramuscular (IM). Whole inactivated influenza vaccine elicit strong 
humoral immune responses and the serum antibody response is dominated by the IgG 
[155], along with mixed cellular responses of Th1 and Th2 cells. Both split and 
subunit IIVs can potentially induce Th2 cell responses beside strong systemic 
antibody responses. The principle mechanism of IIVs is to induce neutralizing 
antibodies to the major surface glycoprotein HA and to a lesser extent to NA. IIV 
therefore induces higher serum HAI responses compare to LAIV. A previous study 
has also demonstrated increased serum HAI response in adults by IIV compare to 
LAIV [156]. Although, IIVs do not mount mucosal immunity, and also have lower 
induction of plasmablast and plasmablast induced polyclonal antibodies specific to 
HA compared to LAIV [157]. 
LAIV is often attenuated by propagation at lower temperature (cold adaptive) leading 
to adaptive gene mutations. The virus strains can additionally be modified by 
replacing the genes from low-pathogenic strains. Thus, LAIV share the internal 
attenuated genes segments which are mutated at least in one or several segments by 
using serial passage at lower temperatures to produce the master donor virus (MDV) 
backbone of cold-adaptive (ca), temperature-sensitive (ts) and attenuated (att) 
phenotype. The MDV backbone then incorporates the HA and NA of annually 
circulating virus strains for the annual LAIV vaccine [158, 159]. Quadrivalent 
FluMist (North America) or Fluenz (Europe) LAIV is available for vaccination 
against influenza infection. LAIV is a licensed as nasal spray and has been used in 
Russia since 1970s, and licensed in USA from 2003 and later in 2012 in Europe. The 
vaccine is well tolerated and generally only minor local side effects occur, such as 
runny and congested nose. The three characteristic benefits of the attenuated virus 
allow replication at the local infection site of respiratory tract and generate immune 
response similar to natural infection. In contrast to IIV, LAIV induce stronger 
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mucosal responses dominated by IgA. T-cellular responses are elicited by LAIV 
beside strong humoral and mucosal immune responses [160]. LAIV provides superior 
protection in young children than the adults due to the T-cell responses [90]. 
Administration of intranasal LAIV elicits long-lasting humoral and cellular responses 
particularly in the upper respiratory tract (Figure 7).  
  
Figure 7. Model of induction of immune responses after live attenuated influenza 
vaccination (LAIV). (1) Intranasal LAIV immunization; (2) Viral antigen is transported to 
the tonsils/adenoids by the Dendritic Cells (DCs); (3) Activation and proliferation of T and 
B-cells in tonsils/adenoids with help from CD4+ T-cells. Affinity maturation of B-cells; (4,5) 
Activated T and B-cells home to the site of infection or enter the circulation. Plasma cells 
secrete antibody into the blood and at the mucosal surfaces. 
 
Our previous study reported that LAIV induce cross-reactive and durable T-cells 
responses in children [161]. LAIV provides protection by promoting HA- specific 
neutralizing antibodies [162] and can also provide heterosubtypic protection [89]. 
LAIV is now included in the childhood vaccination program in UK due to the 
demonstrated effectiveness in children and reduction of community spread of 
influenza and its associated economic burden [163]. 
K.A. Brokstad © 
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1.5.3 Targeting Influenza Vaccines by Age or Gender  
Previous exposures to influenza strains are believed to have a great impact on the 
immune response to future strains. Seasonal vaccines are annually updated to match 
the predicted circulating strains and induce strain specific immunity. Current 
influenza vaccines are standardized by the amount of the most common surface 
glycoprotein, HA, and the antibody response is mainly directed to the mutable and 
highly variable globular head domain of HA. These vaccines mainly do not induce an 
immune response to the immune-subdominant conserved stalk of HA. The frequent 
antigenic drift of the virus due to the high plasticity of the HA can limit vaccine 
effectiveness when the circulating strain has drifted. The number of strains and their 
diversity experienced by an individual in a lifetime including by natural infection or 
vaccination can impact upon the magnitude of immunity that will develop in the 
future. When a novel HA is substantially antigenically changed, infection or 
vaccination an individual can generates response of broadly neutralizing plasmablast 
toward HA stalk. Moreover, infection with closely related influenza strains induce 
neutralizing B-cell response to the globular head [164]. One of the key questions that 
become important to know about the age and exposure history to seasonal and 
pandemic influenza infection. However, it is not still clear how different prior 
exposure confers immunity to circulating influenza virus and/or vaccination. 
Interestingly, a systems analysis suggested that the immune system of an individual is 
defined by specific exposure frequency, that an individual encounters in their lifetime 
[165]. From the experience during the last pandemic in 2009, older people who were 
born in 1940’s had less severe infection due to the presence of pre-existing cross-
reactive anti pdm2009 antibody [166, 167]. Several studies show that the stalk 
specific broadly neutralizing antibodies increase with age due to previous experience 
with divergent influenza viruses [168, 169]. 
Gender differences also play a key role in response to influenza vaccination, e.g. 
testosterone can be immunosuppressive [170]. One of the largest risk group 
recommended for influenza vaccines is the elderly is however immunosenescence; 
the aging of the immune system and progressive to decline of immune functions with 
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age. The hallmark of the aging immune system is chronic low-grade pro-
inflammatory state and occurs to a much greater extent in females than in male. The 
performance of the innate immune cells including dendritic cells, macrophages or 
neutrophils is vastly dysregulated with age under inflammation or pathogenesis [171]. 
Further animal studies suggest that aging promotes dysregulation of T-cell function; 
limiting clonal diversity of naive CD+ T-cells and CD8+ T-cells [172, 173], reduce 
effector memory CD4+ T-cells but with increased central memory T-cells and 
increased effector memory and effector CD8+ T-cells [173, 174]. There is increasing 
evidence that the both innate and adaptive immune responses are different among 
sexes due to exposure to earlier immunological stimuli but are not suitably considered 
during vaccine development. 
The availability of two different influenza vaccines either IIV or LAIV allows 
targeting of the vaccines to the different age groups in which they are documented to 
be most effective. IIV shows higher protection against influenza infection in adults 
compared to LAIV. On the other hand, LAIV vaccination induces better protective 
immune response in children compared to IIV one of the reasons that the European 
Medicines Agency did not licence the LAIV for use in adults in Europe. As LAIV is 
administered intranasally and acts like natural infection, pre-existing immunity in 
older adults may limit the replication of the LAIV strains. The recommendation of 
which groups should be prioritized for seasonal vaccines differs between different 
countries partly based on economic priorities and due to their differing effectiveness 
in different age groups. The quality of the immune response to vaccination and 
natural infection should be addressed in future studies in all age group. As the new 
era for development of both seasonal and pandemic influenza immunization 
continues, research may explain how and why influenza exposure history, priming 
and imprinting, the age difference as well as the gender difference influence vaccine 
uptake, response and outcome. Recent studies demonstrated that potent protection 
were achieved via antigenic seniority and childhood HA imprinting against next 
pandemic potential A H7N9 and A H5N1 strains [106, 107, 175] explaining the age 
distribution of both zoonotic strains and may be useful in predicting the future 
pandemic potential of a virus [176]. 
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1.6 Next Generation Vaccine Strategy And Immunity Involvement 
In principle, next generation vaccines are focused on improvements to current 
influenza vaccines with the ultimate goal of development of the universal vaccine. A 
universal vaccine refers to a vaccine concept that should elicit broadly protective 
immune responses and provide long-lasting protection against seasonal as well as 
potentially deadly pandemic influenza virus strains. The reason universal vaccines 
have been nearly impossible to develop lies in the nature of the influenza virus 
surface glycoproteins, especially the haemagglutinin (HA). Current influenza 
vaccines are dependent on the induction of the neutralizing antibodies towards the 
globular head domain, which directly neutralizes the virus preventing attachment. 
The HA is highly variable among different virus strains and vaccines are most 
effective if the vaccine virus strain is well matched with the circulating strain. 
Typically, the available licensed vaccine confers protection against seasonal vaccine 
ranging from 10%-60% depending on the antigenic match between circulating and 
vaccine strains, and require annual updating of vaccine strains. Seasonal vaccines 
elicit strain specific antibodies and provide little to no protection against newly 
emerged pandemic influenza viruses and so immediate production of a pandemic 
vaccine is required. The world has already experienced four devastating pandemic in 
20th and 21st century and the first recognised pandemic in 1918 was the worst on 
record. The very recent 2009 pandemic was relatively mild but showed the lack of the 
entire global capability to produce sufficient number of vaccine doses for the whole 
world [177, 178]. Thus, the obvious solution discussed during the last decade is for 
universal vaccine development, which may become achievable in the near future. A 
consensus among experts on the criteria can be set up as a universal vaccine is 
needed. Thus scientists from national institute of allergy and infectious diseases 
(NIAID) at the NIH and collaborators suggest a universal “vaccine with ≥ 75% 
protection against symptomatic influenza disease infected by groups I and II 
influenza A viruses lasting over a year in all populations” [108]. The major 
challenges for universal vaccine development are, I. understanding the differentiation 
of the immune response upon natural infection or vaccination in all ages. II. To map 
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the evolutionary capabilities of influenza viruses that make the virus to escape the 
host defence. Several concepts are being studied further to overcome the lack of 
knowledge, like original antigenic sin (OAS), antigenic seniority and /or antigenic 
imprinting to achieve the immunological knowledge for the next generation vaccines. 
Since the discovery of the OAS concept in 1960s by Thomas Francis Jr and 
colleagues, the theory has been challenged but gained critical information about how 
the previous exposure to influenza virus infection shapes antibody responses for 
further infection or vaccination [179, 180]. The ‘original antigenic sin’ concept 
explains the influence of the first influenza virus experience on lifelong immunity 
[181]. Antigenic seniority or antigenic imprinting might be more appropriate as these 
describe the phenomenon of OAS and how childhood influenza experience takes a 
superior position over the immune response [182, 183]. The memory responses 
remain higher than to subsequent infection with a similar strain type [184]. 
The rapid evolutionary capabilities of influenza virus strains makes it more 
complicated to design universal vaccines. More conserved epitopes lies in the HA 
stalk compared to the high mutable globular head domain. Studies have shown that 
both seasonal and pandemic vaccine can induce broadly cross-reactive antibody 
responses specific to the HA stalk. The majority of broadly neutralizing antibodies 
identified target the epitopes on the stalk domain and epitopes are conserved across 
the group 1 or group 2 [185, 186]. To overcome the limitations of HA head based 
conventional vaccines, HA stalk based influenza virus vaccines are now considered 
as potential candidate universal vaccine and have entered phase I human clinical trial. 
In principle, the next generation HA stalk based vaccine will induce immunity against 
both group I and group II stalk epitopes and will confer protection against any drifted 
or shifted influenza virus strain [187-189]. Two different approaches have been 
described in studies, where, the entire head domain is removed to construct the 
headless stalk as first strategy. A recent study has shown protection against both 
group I and group II influenza viruses using mini stalks from group I HA [190, 191]. 
The second approach is to construct chimeric HAs containing the stalk domain from 
H1, H3 or influenza B virus with the head domain of exotic virus strains not known 
to infect humans [192, 193]. Studies in mice and ferrets describe the protective 
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immune response by sequential vaccination with chimeric HAs. Importantly, 
immunization by different routes and using adjuvants effectively boosted long-lasting 
anti-stalk antibodies [194-197].  
Besides the HA stalk based approach, other vaccination strategies have been 
introduced in the last decades that target broad immunity against influenza strain 
variants. For example, a computational method was used to produce consensus 
sequences of all strains. Computationally-optimized broadly reactive antigen 
(COBRA) were generated, where, consensus antigen sequence consisted of conserved 
epitopes across all isolates combining the most common amino acids undergoing 
frequent changes which remain in their respective positions. The computationally 
customised antigen sequences induce cross-reactive antibodies [198, 199]. This 
strategy has resulted in promising outcome and elicited protective immune responses 
against pre-pandemic H5N1 and also seasonal H1 and H3 viruses [200, 201]. 
Immunization with virus-like particles (VLPs) containing HA provides broad 
protection and protects mice against multiple subtypes of influenza A virus [202]. 
Moreover, conserved peptide pools from HA were also tested with adjuvants and 
conjugated bacterial protein to assess the potentiality as next generation vaccine [203, 
204]. More recently, live attenuated vaccine is used as the newest strategy that 
confers broad protection and currently (2017) is undergoing the clinical trial. The 
approach to use both inactivated vaccine (IIV) priming following live-attenuated 
vaccine (LAIV) boosting is considered as a novel strategies for the development of 
the next generation vaccine. Live attenuated vaccination approach had given 
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2 Aim of the Study  
The study aimed primarily to elucidate the humoral and cellular immune responses 
after live attenuated influenza vaccine (LAIV) in children and adults in blood and 
tonsils collected during a clinical trial conducted at Haukeland University Hospital 
(HUH). 
The major secondary objectives are 
• To evaluate influenza A HA head and stalk specific antibody responses 
after LAIV immunization. 
• To investigate the HA and NA specific humoral and cellular H1N1pdm09 
responses following LAIV vaccination. 


















3 Study Design 
3.1 Clinical Vaccine Trial 
Our LAIV vaccine clinical trial was conducted in children in 2012-13 and in 2013-14 
in adults. The clinical trial is approved by the regional ethical committee (REC West 
2012/1088) and the Norwegian Medicines Control Agency. The trial was registered 
in the open access databases; EUDRACT2012-002848-24 and 
www.clinicaltrials.gov; NCT01866540. The clinical trial involved collaborative work 
between the Influenza Centre, the Paediatric clinical trial unit and the Ear Nose and 
Throat (ENT) departments at the Haukeland University Hospital (HUH). Written 
informed consent from adults and parents (and children over the age of 12) were 
collected before enrolment in the study. Children and adults were recruited from the 
elective tonsillectomy lists during their initial outpatients visit.  
Fifty-five children were included in the trial and 39 children were vaccinated and 16 
unvaccinated children were included as age and sex matched controls. Twenty-four 
healthy adults were recruited and 20 were vaccinated during 2013-14 season (Figure 
8). Children under the age of 9 years old received two vaccine doses at 28 days 
interval, whereas older children and adults received a single dose. The vaccine was 
administered intranasally according to the manufacturer’s instructions. LAIV was 
administered as a divided dose of 0.1ml per nostril. After vaccination, all subjects 
remained under observation by the study staff for at least 30 minutes. 
The inclusion criteria were designed for healthy children or adults with no fever or 
symptoms of influenza-like illness during the 7 days prior to vaccination, subjects 
with mild or moderate asthma (with daily use of inhaler) were included and females 
of child bearing age had to have a negative pregnancy test before vaccination.  
Children or adults were excluded if they suffered from chronic or serious medical 
conditions like, unstable asthma, recent influenza or high fever, pregnancy, use of 
acetyl salicylic acid (ASA) or were taking immunosuppressive therapy. Also subjects 
who were allergic to the vaccine or its components or children under governmental 
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custody were excluded. During the time of trial LAIV vaccine was not licenced in 
Norway, but imported from Finland and UK solely for this study. For all subjects, 
demographic information was collected such as age, sex, weight and height for 
children, underlying disease and previous seasonal vaccination or pandemic 
vaccination. 
 
Figure 8. Overview of the live attenuated influenza vaccine clinical trial. The adults and 
children were recruited from the operation list scheduled for elective tonsillectomy from ear, 
nose and throat (ENT) department. Subjects were vaccinated with LAIV at 2-5, 6-9 and >10 
day prior to tonsillectomy. Blood samples were collected prior to tonsillectomy (day 0), at 
the time of tonsillectomy and up to one year (day 28, 56, 180 and day 360) after vaccination. 
A control group of children was included for paper III to provide a pre-vaccination 
comparison to post vaccination tonsillar T-cell responses. 
3.2 Immunization And Sampling in Following Study 
Children received one (≥9 years old, n=6) or two doses (<9 years old, n=14) of LAIV  
(Fluenz, Astra Zeneca, Liverpool, UK) in 2012 at a four-week interval, whereas 
adults received a single dose in 2013-14 seasons [161]. Blood samples were collected 
pre-, at elective tonsillectomy, and at regular intervals after vaccination (28, 56, 180 
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and 360 days). Plasma was aliquoted and frozen for use in the serological assays, as 
previously described and illustrated in Figure 9 [206]. Cell preparation tubes (CPT, 
BD) were used to separate peripheral blood mononuclear cells (PBMCs) for the 
ELISpot assay. Fresh PBMC were immediately separated by centrifugation (density 
gradient) and used directly in cellular assays in the paediatric population otherwise 
stored in liquid Nitrogen. During the operation, tonsils were operated as scheduled at 
2-21 days after first LAIV immunization and collected (in 0.9% NaCl) by the 
assigned doctors from ENT department, working as the part of the project. 
Lymphoprep (Stemcell tech. UK) was used to isolate tonsillar mononuclear cells 
(TMCs), which were analysed in cellular assays. Briefly, manual disruption of the 
tonsils was carried out using forceps and scalpel and filtered before density gradient 
centrifugation separation of lymphocytes. 
Figure 9. Study design. Adults were vaccinated with one dose of LAIV, whilst children 
received either 1 (n = 39) or 2 (n = 29 children, age < 10 years old). Plasma samples were 
collected prior to tonsillectomy and vaccination as pre (day 0) and after tonsillectomy or at 
28, 56, 180 and 360 days post vaccination. Tonsil samples were collected at 3, 7 or 14 days 
post vaccination in children. The figure shows the number of adults and children at each 
sampling point and the papers (I-III) these samples were used in. 
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3.3 Participants in the Study   
Subjects were intranasally immunized with 0.1 mL per nostril of the seasonal LAIV 
(Fluenz, Astra Zeneca, Liverpool, UK) in the clinical trial conducted in 2012-14. The 
exclusion criteria and study details for this clinical trial have been published earlier 
and are described above [161].  
3.4 Vaccine 
Trivalent LAIV (Fluenz) contained 107 fluorescent focus units (FFU) of 
A/California/7/2009(H1N1)pdm09-like and A/Victoria/361/2011(H3N2)-like strains 
in both seasons, with either B/Wisconsin/1/2010-like or B/Massachusetts/2/2012-like 
in the 2012-13 or 2013-14 seasons, respectively.  
3.5 Recombinant Haemagglutinin Proteins 
The influenza A haemagglutinin proteins were prepared for use in the ELISA by 
using the baculovirus expression system (Paper I, Table 1) [207, 208]. The chimeric 
stalk HAs were prepared by using an irrelevant head domain, from a virus which does 
not cause human infection. The cH6/1 contained the globular head domain from 
A/mallard/Sweden/81/02 (H6N1) and the stalk domain from A/PuertoRico/1/34 
(H1N1). The cH4/3 contained the H4 globular head domain from A/duck/Czech/1956 
(H4N6) in combination with the H3 stalk domain from A/Perth/09 (H3N2). 
3.6 Antigens and Peptides 
A/California/7/09 (H1N1), A/Victoria/361/2011 (H3N2) and B/Wisconsin/1/2010 
split virus antigen from the vaccine strains were kindly provided by GSK (Glaxo 
Smithkline, Belgium). By mapping the sequence diversity, HLA supertype, 
prevalence and the influenza isolates spanning from 1934-2009, a panel of T-cell 
epitopes were selected. The panel contains 33 peptides covering cross-reactive CD4 
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epitopes and 31 peptides from CD8 [209]. The peptides with the highest sequence 
stability were further selected from the panel to know the cross-reactive immune 
response against viral strains. The peptide library was kindly provided by the 
Norwegian Institute of Public Health (NIPH) consisting of peptides for H1N1pdm09 
(see paper II supplementary materials) and cross reactive CD4 and CD8 peptides (see 
paper III supplementary table). Fmoc chemistry (Mimotopes, Clayton, Australia) 
were chemically synthesized the peptides supplied in 100% DMSO with a 
concentration of 20mg/ml. Stock concentration (8µg/ml) were made by diluting in 
RPMI media and working concentration of 2µg/ml were prepared before running the 
IFN-γ ELISpot assay. 
3.7 Viruses Used 
Viruses were propagated in the allantoic cavity of 10 days old embryonated hen’s 
eggs. The allantoic fluid was harvested, clarified and frozen at -80oC until used in the 
assays as described below. The reassortant A/California/7/2009(H1N1) virus (x179a) 
was used for the micro-neutralization (MN) assay, the chimeric H1N1 virus (cH9/1 
containing the HA stalk from A/California/7/2009(H1N1) and head from A/guinea 
fowl/Hong Kong/WF10/99 for the virus neutralization (VN) assay, and the reverse 
genetics A H7N1 virus (NIBRG-127 containing the NA from 
A/California/7/2009(H1N1) and HA from the equine A/Prague/56 (H7N7) strain) for 
enzyme-linked lectin assay (ELLA). The wild type A/California/7/2009(H1N1) virus 
was used for the antibody dependent cellular cytotoxicity (ADCC) assay. 
3.8 Statistics 
Statistical analyses were performed in Paper I by linear mixed model using 
STATA/IC 14.1 for Mac (StataCorp, College Station, TX 77845, USA) where, 
geometric mean titres with 95% confidence interval were used to investigate 
statistical differences between different time points after vaccination. GraphPad 
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Prism, version 6f for Mac (GraphPad Software, San Diego, California) was used for 
Wilcoxon test for head/stalk distribution between time points after vaccination.  
Statistical differences (Paper II) from pre-vaccination to 56 days post vaccination in 
children and adults were analysed using the Wilcoxon-matched pairs signed rank 
tests. The nonparametric Mann-Whitney test was also used for comparing children 
and adult antibody responses in multiple assay analysis (GraphPad Prism; v.6f for 
Mac, GraphPad Software, USA), where, P < 0.05 was considered significant. In 
Paper III, differences between pre- and post-vaccination immune responses were 
analysed by non-parametric Kruskal-Wallis multiple comparisons test or the Mann-
Whitney test using GraphPad Prism version 6 for Mac OS X. The correlation analysis 
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4 Methods & Consideration 
4.1 Haemagglutinin Inhibition (HI) Assay 
Plasma samples were pre-treated with four volumes of receptor destroying enzymes 
(RDE) (Seiken, Japan) overnight and heat inactivated at 56oC for 30 minutes. The HI 
assay was performed in duplicate using serial 2-fold dilutions (starting dilution 1:10) 
of RDE treated plasma and eight hemagglutinating units of either influenza 
A/California/04/09 (H1N1), A/Victoria/361/11 (H3N2) or B/Wisconsin/1/2010 and 
0.7% (v/v) turkey erythrocytes. The individual HI titres were read as the reciprocal of 
the highest dilution at which 50% haemagglutination was inhibited. Titres <10 were 
assigned a value of 5 for calculation purposes. The geometric mean titre (GMT) was 
calculated for each subject and for each group at each time point.  
Methodological Consideration  
Quantification of influenza-specific antibodies against different influenza strains is 
important to know the level of pre-existing immunity and the response to LAIV. 
Based upon the properties of influenza virus to agglutinate the erythrocyte, the HI 
assay can be used with human sera to measure the inhibitory antibody concentration 
[210] .  There are several methods to quantify viral strain specific antibodies but the 
HA inhibition assay is commonly used and immensely reliable to detect antibodies to 
the circulating viruses in sera. The HI method is globally used for influenza 
surveillance for determining antigenic properties of emerging viruses. One of the 
major drawbacks of the HI assay is that the non-specific inhibition of 
haemagglutination can interfere with the assay. Therefore, sera must be pre-treated 
with RDE and in some cases sera need to be pre-treated with packed red blood cells 
to removed non-specific inhibitors which can interfere with the HI assay [211]. All 
the LAIV plasma samples included in this study were run in the HI assay. In adults an 
HI titre of 40 is considered to provide protection in 50% of adults. The assay is 
shown in the illustration below in Figure 10. 
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Figure 10. Principle of the haemagglutination inhibition (HI) assay. 
4.2 Enzyme-Linked Immunosorbant Assay (ELISA) 
Nunc Maxisorp 96-well immunoplates (eBioscience, Inc., USA) were coated with the 
appropriate HA protein (0.1 µg/well) in phosphate buffered saline (PBS) (Medicago 
AB, Uppsala, Sweden) overnight at 4°C (paper I, table I). After blocking with PBS 
containing 5 % skimmed milk powder (Sigma-Aldrich Co., USA), 1 % Bovine Serum 
Albumin (BSA) (Sigma-Aldrich Co., USA) and 0.1 % Tween-20 (Sigma-Aldrich 
Co., USA), plasma samples were diluted in 5-fold dilution series from 1:50 to 
1:312500 in blocking buffer and incubated for 1 hour at 37 °C. After washing, 
specific serum antibodies were detected by mouse monoclonal anti-human IgG 
conjugated with horseradish peroxidase (HRP) (BD; USA) (1:4000 dilution for 1 
hour at 37 °C) and developed with 3,3', 5,5' tetramethylbenzidine (BD; USA) for 10 
minutes. The reaction was stopped using 100 µl per well of 0.5 M HCl and the plates 
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were read immediately at 450 nm using BioTek synergy H1 hybrid reader. The end 
point titres were calculated using the mean of the blank plus three standard deviations 
as a cut off [105]. 
Methodological Consideration  
The indirect ELISA has been widely used for detection of influenza strain specific 
antibodies. The method is suitable for detecting antibodies to the coated antigen, e.g. 
haemagglutinin (HA). Recently, the newer methods are using continuous readout 
mPLEX-Flu assay to measure the concentration of anti-HA IgG antibodies against 
HAs from multiple influenza virus strains. The assay is Luminex-based that can be 
used against up to 50 influenza strain or particularly HA proteins using reduced 
amount of serum samples [212]. Indirect ELISA is more sensitive than any other 
conventional assays used previously [213]. As an example, single radial haemolysis 
(SRH) assay, first used by Weiler, Melletz and Breuninger Peck in 1965 and later 
used to widely detect antibodies against influenza HA [214, 215]. On the other hand, 
ELISA was developed at the same time to detect antibody against a variety of viruses 
[216] and the method has good sensitivity [217] and is more convenient to perform 
with collected blood samples. In the conventional serological assays, antibodies to 
influenza A H5 and H7 avian strains require higher biological containment if working 
with live virus. These problems can be overcome by expressing the HA proteins in 
the baculovirus system and detecting antibodies in ELISA using influenza strain 
specific surface antigens [218-220]. We preferentially chose the indirect ELISA to 
measure influenza specific IgG antibody in the plasma. The protocol has been 
developed in our lab to measure the antibody responses to different influenza 
haemagglutinin constructs and measures the optical density (OD) by using 
colorimetric substrate under spectrometry. 
4.3 Micro-Neutralization (MN) Assay 
The Microneutralization assay was conducted as previously described [206]. Briefly, 
plasma samples and control sheep sera were serially diluted from 1:10 using double 
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dilutions in flat-bottom 96-well cell culture plates (Nunclone Delta surface, USA) 
before incubation with 100 TCID50/50 µl/well of A/California/04/09 (H1N1) (x179a) 
for 1 h at room temperature. Then, 1.5x105 Mardin Darby canine kidney (MDCK) 
cells/ml were added in DMEM media contained 1% FBS (filtered) and 1% PSA. 
15000 cell/well were plated and incubated for 16-18 hours at 37°C. The propagation 
of influenza virus was detected using antibody (dilution; 1: 5000) to the nucleoprotein 
and TMB (3,3ʹ, 5,5ʹ-Tetramethylbenzidine; Thermo Fisher Scientific, USA) before 
reading at 450nm and 620nm to obtain the final optical density (OD). The 
Microneutralization titres (IC50) were calculated using the Reed and Muench method. 
Methodological Consideration  
The microneutralization assay (MN) is the most reliable functional assay to measure 
the level of neutralizing antibody.  Both HAI assay and MN assay primarily detect 
antibody directed to the HA, although the HAI assay measures antibody which 
inhibits haemagglutination and can be used with inactivated virus. The MN assay is 
highly sensitive and specific for detecting functional neutralizing antibodies to a 
given influenza virus strain [221]. The main advantage of the MN method is that the 
assay can be rapidly carried out if a novel virus emerges and the infectious virus is 
available. The drawback of the assay is that the conventional neutralization assay is 
based on measuring inhibition of cytopathogenic effect in MDCK cells and requires 
long incubation times. The ELISA based MN assay using microtiter plates with virus-
infected cells can provide serum neutralization titres within two days. Initially the 
50% tissue culture dose or TCID50 is calculated [222] to allow standardization of the 
virus in the assay. Although, the MN titres is usually correlated with HAI titres, the 
MN assay is more sensitive and mechanistically relevant in estimation of antibody 
mediated protection; for an example, HAI titre of  > 40 is considered as the protective 
titre corresponds to the MN titre of  >80 (or in some cases > 160) [223, 224]. 
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4.4 Virus-Neutralization (VN) Assay 
The virus neutralization assay was conducted with the cH9/1 virus using a 3-day 
incubation period [225, 226]. Briefly, cell culture plates (Flat-bottom 96-well 
Nunclone Delta surface, USA) were seeded with 1.5×105 MDCK cells and incubated 
at 37°C overnight. Next, heat-inactivated plasma samples were diluted to 1:10 and 2-
fold serially diluted before incubation with cH9/1 (100 TCID50/50 µl) for 1 h at room 
temperature. MDCK cells were washed with PBS, and plasma/virus dilutions were 
added and incubated for 1-h incubation at 37°C. The mixture was removed, cells 
were washed with PBS, and 50 µl of serially diluted plasma plus 50 µl infection 
medium (DMEM medium containing 2.5mg/ml TPCK-treated trypsin (Worthington 
Biomedical, USA), PSA (100 IU/ml penicillin, 100mg/ml streptomycin and 0.25 µg 
fungizone; Lonza, Switzerland) and 0.14% bovine serum albumin (Sigma-Aldrich, 
USA) were added to each well before incubation at 37°C for 72 h. The virus 
neutralization titres were measured by haemagglutination assay using the supernatant 
(50 µl) and 50 µl of 0.7% human red blood cells and read after 30 min of incubation 
at room temperature. The highest dilution of plasma resulting in 100% 
haemagglutination was read as the neutralizing antibody titre. A value of 5 was 
assigned to samples below the limit of detection for statistical analysis. 
Methodological Consideration  
The neutralization assay has uniquely been recently established to target the HA stalk 
specific neutralizing antibody. The conventional neutralization assay generally 
measures HA head specific functional antibodies when using human influenza 
viruses, which interfere with detection of stalk specific antibodies. Therefore, the 
chimeric HA based influenza virus strain was designed with the stalk combined with 
an “exotic” head domain derived from influenza virus subtype which does not infect 
man and an irrelevant N3 neuraminidase [225]. The cH9/1 virus was generously 
provided by Florian Krammer to use in vitro to infect MDCK cells followed by 72 
hour incubation to detect antibody to the conserved stalk epitopes. This virus allows 
detection of functional antibodies specifically to the HA stalk domain rather than the 
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head specific antibodies due to the exotic head which has not circulated in humans 
[193].  
4.5 Enzyme-Linked Lectin Assay (ELLA) 
The ELLA was used to measure antibodies inhibiting the ability of neuraminidase to 
cleave sialic acid. The reverse genetics influenza A H7N1 virus containing the HA 
from an equine influenza A H7 strain and NA from A/California/07/09 (H1N1) was 
used as previously described [227-229]. Briefly, 96-well flat bottom Maxisorb plates 
(VWR, USA) were coated with 100 µl fetuin (Sigma-Aldrich, USA) in 25 µg/ml 
coating solution (KPL; Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA) at 
4°C overnight. Plates were washed three times with T-PBS (PBS with 0.05% Tween-
20) before adding serially diluted serum (heat-inactivated at 56°C for 45 minutes) and 
24 µl H7N1 virus (1:10 dilution) and incubating at 37°C for 16-18 hours. Plates were 
washed six times with T-PBS and Horseradish peroxidase (HRP)- conjugated peanut 
agglutinin (PNA) (Sigma-Aldrich, USA) was added (100 µl, 1 µg/ml) and incubated 
at room temperate for 2 hours. The plates were then washed three times with T-PBS, 
and o-phenylenediamine dihydochloride (OPD) (Sigma-Aldrich, USA) substrate 
(0.5mg/ml) in citrate buffer was added to all wells. After 10 min incubation at room 
temperature in the dark, the reaction was stopped with 100 µl 1 M sulphuric acid. The 
plates were read with a microplate reader by spectrophotometry at OD 490 nm. The 
anti-NA antibody titres (EC50) in the plasma samples were calculated as the 
reciprocal dilutions of plasma with gave OD values equal to 50% of (OD virus 
control + OD blank) in four-parameter non-linear regression analysis using GraphPad 
Prism. 
Methodological Consideration  
Neuraminidase is the second major surface glycoprotein of influenza virus and plays 
important roles in both virus attachment and release from infected cells, although, not 
as abundant as HA. Inhibition of NA activity reduces virus plaque size in vitro and 
NA inhibiting (NAI) antibodies also correlates with protection against H1N1 in 
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healthy human challenge model [230]. Therefore, NAI antibodies could lead to 
decreases in viral shedding after infection and also reduce replication of LAIV strains 
after vaccination. Although, the NA function is crucial and important to prevent 
influenza, the traditionally established NI assay has not been included in past 
influenza immunogenicity epidemiology studies. The traditional NI assay was first 
described by Webster and Laver in 1967 and follows the assay procedure of Warren 
and Aminoff in 1959 described quantification of free sialic acid [231]. Another NA 
assay is the thiobarbituric acid (TBA) method but is impractical for routine serology 
due to the use of hazardous chemicals that convert sialic acid into a chromophore. 
The miniaturized assay was then developed in 1990 by Lambre et al. known as 
enzyme-linked lectin assay (ELLA) that quantifies the enzyme activity using peanut 
agglutinin (PNA) [232]. The PNA binds to the galactose moieties that are cleaved and 
exposed after the NA enzymatic reaction. The NA inhibiting antibodies are quantified 
after overnight incubation using a colorimetric readout and antibody titres calculated. 
The ELLA can also be used to compare the antigenic properties between the NAs of 
the circulating influenza strain. 
The ELLA assay is now widely accepted and used as alternative of neuraminidase 
inhibition (NI) assay, but there are some major considerations that need to be taken 
into account. First of all, the test sample containing NA specific antibody will 
probably also bind HA. The presence of HA specific antibodies therefore interfere 
with NA binding in a competitive way [233] and are often underestimated due to the 
presence of high quantity of HA on the surface of the virus. To avoid this non-
specific inhibition by HA-specific antibodies, we used the reverse genetics generated 
wild type N1 virus containing antigenically-mismatch HA. Secondly, some NA 
subtypes enzyme activity is greatly reduced at pH >7.0, therefore the recommended 
pH 6.5 of the buffer can be adjusted during the virus titration. Overall to minimize the 
other non-specific inhibition, the serum samples were heat-treated at 56 °C for 45 
min. In contrast to the conventional NI assay, ELLA is easier to perform with a large 
number of samples and easier to read without using harmful chemicals. Most 
importantly, the other studies demonstrated the assay result is reproducible and plate–
to-plate variability is minimum [234, 235].  
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4.6 Antibody Dependent Cellular Cytotoxicity (ADCC) 
The ADCC Reporter Bioassay (Core Kit G7010/G7018, Promega, USA) was used to 
quantify pre- and post-vaccination ADCC antibodies [51]. MDCK cells as ‘target 
cells’ (at 1.5x104 cells/well) were seeded in 96 F-well white tissue culture plates 
(VWR, USA). After overnight incubation (18-24 hours), cells were infected with wild 
type A/California/7/2009(H1N1) virus at a multiplicity of infection (MOI) of 3. On 
the day of the assay, the medium was replaced with assay buffer (RPMI 1640 with 
4% (vol/vol) low IgG FBS; Lonza, Switzerland), followed by the addition of 5-fold 
serial dilutions of plasma (starting at 1:10). The infected cells were incubated 
together with antibodies at 37 °C for 30 min. The effector cells (Jurkat) at 7.5x104 
cells/well were added to the assay plates. After 6 hours incubation at 37 °C, the Bio-
GloTM luminescence assay (Promega, USA) system was used to quantify using a plate 
reader with glow-type luminescence. 
Methodological Consideration 
ADCC is a non-phagocytic killing process of an antibody coated infected cell (target 
cell) conducted by cytotoxic effector cells. ADCC was first described in natural killer 
cells (NK) by Moller in 1967 [236], but can also involve monocytes, macrophages, 
dendritic cells, neutrophils and eosinophils. The conserved HA stalk specific 
antibodies have been shown to increase ADCC activity [225]. After interaction with 
target cell bound antibodies (typically, IgG, IgE or IgA) through FcγRIIIa (CD16) 
signals initiate the expression of cell death molecules or release of cytotoxic granules 
triggering ADCC. NK-cells have a majority of FcγRIII that interact with the 
influenza specific antibody. Therefore, further understanding of the mechanism of 
ADCC is crucial to understand the immune response to current vaccines and develop 
future influenza vaccines. The conventional ADCC assay activates the CD16 receptor 
in primary NK cells and uses flow cytometry for detection of degranulation and IFN-
γ, it is labour intensive and expensive.  On the other hand, the ADCC reporter 
bioassay is commercially available and standardised in a 96-well plate format. The 
assay has good precision, is biologically relevant and provides good reproducibility 
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[50]. Importantly, to quantify the pre- and post-vaccination ADCC antibodies, cell 
culture is not required in the reporter bioassay and the assay is rapid to perform.  
4.7 ELISpot Assay 
Antigen-specific interferon (IFN) γ+ cytokine-secreting T-cells were quantified at the 
single-cell level by the ELISpot assay (Mabtech AB, Sweden) [237]. Optimized 
libraries of peptides representing unique T-cell epitopes from four of the initial 
H1N1pdm09 circulating strains were used for measuring H1N1pdm09 specific CD4+ 
(originating from HA, NA, M1, NP, PB2) and CD8+ (M1, NA, PA and NS2) 
responses (Paper II). Optimized libraries of broadly reactive CD4+ and CD8+ -
conserved peptide pools were used in Paper III. Briefly, 400000 PBMCs or TMNCs 
per well were stimulated with appropriate CD4+ and CD8+ peptide pools (2 µg/mL), 
anti-CD3 T-cell activator (positive control), or lymphocyte medium alone (negative 
control) [209]. Plates were incubated overnight at 37°C, 5% CO2. Plates were then 
developed the following day by following the manufacturer’s instruction and read 
using an automated reader (Advanced Imaging Devices), where spot-forming units 
(SFUs) were counted. The background values were subtracted from the influenza 
virus-specific (H1N1, H3N2, B or peptide panel) responses. 
Methodological Consideration  
ELISpot assay was used to quantify the influenza specific T-cell responses pre- and 
post-LAIV immunization. The ELISpot assay was developed measures IFN- γ release 
at a single cell level [238]. The advantages of the assay is its high sensitivity, results 
are consistent in different laboratories and reproducible [239]. The assay has been 
increasingly used in infectious disease studies for quantitative assessment of antigenic 
specific T-cell responses from peripheral blood mononuclear cells (PBMC) to 
understand the role of T-cell immunity after infection or vaccination. Several studies 
demonstrated that pre-existing CD4+ and CD8+ T-cell responses are highly cross-
reactive and provide protection from influenza infection [209, 240]. Therefore, the T-
cell mediated responses to highly conserved proteins may guide development of 
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universal influenza vaccines. On the other hand, the cytokine ELISA assay or 
cytokine bead array can also measure the cytokine release by the activated T-cells 
although they are often less sensitive and reproducible.   
4.8 Multiplex Cytokine Assay 
We used the multiplex assay to analyse the Th1, Th2 and Th17 responses after LAIV 
in the systemic (blood, PBMC) and local (tonsils, TMC) compartments. Due to the 
limited volume of blood samples a mixture of three influenza split antigens (2.5 
µg/ml) from A/H1N1, A/H3N2 and B were incubated in lymphocyte medium with 
1x106 cells/well (TMCs and PBMCs) for 72 hours as previously described [241]. 
Medium alone was used as a negative control and positive controls contained T 
lymphocyte mitogen (Phorbol myristate acetate (10ng/ml) and ionomycin (250ng/ml) 
(Sigma-Aldrich, USA). The supernatant was frozen at -80°C and later thawed for 
assessing GM-CSF, IL-2, IFN-γ, TNF-α, IL-4, IL-5, IL-10, IL-12, IL-13 and IL-17 
by the Bio-Plex system. The concentrations of cytokines in the supernatants was 
analysed by following manufacturer’s instructions and interpolation of cytokine 
concentrations from standard curves. The negative control unstimulated samples were 
subtracted from the influenza specific responses for data analysis.  
Methodological Consideration  
Cytokines act as effectors or modulators in the innate or adaptive immune system 
after influenza infection or vaccination and play an important role in development 
and control of the immune response. Measuring a broad range of cytokines following 
influenza infection or vaccination therefore provides an insight into the influenza 
pathogenicity or immunogenicity [242]. The multiplex cytokine assay is now widely 
used to allow simultaneous detection of a number of cytokines from the same sample, 
which is particularly important in studies of young children where only small 
volumes of blood can be collected. The method is also appropriate for longitudinal 
studies of influenza responses where changes in cytokines are important [243]. The 
assay has a higher level of sensitivity and is able to detect circulating multiple 
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5 Summary of Results 
The influenza centre conducted a clinical trial on live attenuated influenza vaccine 
(LAIV) in children and adults scheduled for elective tonsillectomy in the influenza 
seasons 2012-13 and 2013-14. Plasma samples, and peripheral blood mononuclear 
cells (PBMCs) were collected before, and up to 1-year after vaccination. Tonsillar 
mononuclear cells (TMNCs) were collected during tonsillectomy from individuals 
receiving LAIV, as well as a group of age matched control individuals without 
vaccination. With these clinical samples, we investigated the kinetics and longitudes 
of humoral and cellular immune responses after LAIV in children and adults. 
Paper I (Vaccine 2017) 
Pre and post LAIV vaccination (days 0, 28 56, 6 months and 1 year) plasma samples 
were used to study the humoral immune responses in children and adults with HI and 
ELISA assays. 
The neutralizing antibody responses against HAs from homologous strains were 
measured in HI assays. LAIV elicited significant increase in neutralizing antibodies 
against H3HA up to a year, but not H1HA, in children. LAIV didn’t induce antibody 
responses against H1HA or H3HA in adults. Interestingly, children had higher level 
of H1HA specific pre-existing antibodies compared to adults, while similar levels of 
H3HA specific pre-existing antibodies were found in both children and adults. 
The cross reactivity of the LAIV elicited antibodies was assessed in ELISA with H1 
and H5 for group 1 HA, and H3 and H7 for group 2 HA. Similar to HI results, we 
observed significant increase in the amount of H3HA specific antibodies, but not 
H1HA specific antibodies, up to a year after LAIV in children. Of note, the amount of 
H7HA specific antibodies also significantly increased after LAIV, but no change was 
found in antibodies against H5HA in children. LAIV didn’t induce any noticeable 
antibody increase in adults. Intriguingly, children had higher and similar level of H1 
and H3 specific antibodies, but lower amounts of H5HA and H7HA specific 
antibodies before LAIV vaccination. 
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To dissect HA head or stalk domain specific antibody responses, plasma samples 
were tested in ELISA coated with H1 head, H1 stalk, H3 head or H3 stalk. In 
children, LAIV elicited significant increase in H3 head specific antibodies, and slight 
increase in H1 stalk specific antibodies, although not significant. In adults, the 
amount of antibodies didn’t change after LAIV. Notably, children had higher and 
similar level of H1 and H3 head specific antibodies, but lower level of H1 and H3 
stalk specific antibodies before LAIV vaccination. 
Paper II (Scand. J. Immunol, revision resubmitted) 
LAIV elicits multifaceted immune responses, and we observed increase in H1 stalk 
specific antibodies in children after LAIV. In paper II, we move on to investigate the 
LAIV elicited H1N1 specific antibody and T-cell responses more comprehensively, 
using plasma samples before, 28 and 56 days after LAIV with MN, VN, ELLA, 
ADCC, and ELISpot assays. 
To confirm the H1 stalk specific antibody responses after LAIV in children, we 
performed MN assay with the vaccine autologous A/H1N1Cal09 virus, and VN assay 
with a reassortant virus cH9/1N3, which carries a chimeric HA of irrelevant H9 head 
and H1 stalk, together with an irrelevant N3NA. In agreement with the HI and ELISA 
results in paper I, no increase in H1N1 specific neutralizing antibodies was found in 
children or adults. However, VN assay with the cH9/1N3 virus revealed a slightly 
elevated level of H1 stalk specific antibodies in children after LAIV, confirming the 
ELISA results from paper I. As expected, LAIV elicited no antibody responses in 
adults. Interestingly, when children and adults were further stratified, children and 
adults who had received earlier pandemic or seasonal vaccine(s) had higher pre-
existing neutralizing antibody titres in MN assay than individuals who had not 
received pandemic or seasonal vaccine(s) prior to LAIV vaccination. 
Next, we measured the amount of antibodies, which inhibits NA enzymatic activity, 
before and after LAIV in children and adults with ELLA, in which a reasserted A 
H7N1 virus carrying irrelevant H7HA and N1NA from the vaccine autologous 
A/H1N1Cal09 virus. Of note, LAIV elicited significant increases in NA inhibiting 
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antibodies in children, and to a lesser extend in adults. Interestingly, children had 
higher level of NA inhibiting antibodies before LAIV vaccination compared to adults. 
ADCC plays important roles in eliminating infected cells and reduce disease severity. 
We continued to quantify the vaccine autologous A/H1N1Cal09 virus specific 
antibodies, which is capable of inducing ADCC. LAIV induced H1N1 specific 
ADCC antibody increase in children, but not in adults. Unlike NA inhibiting 
antibodies, children had lower amount of ADCC antibodies before LAIV vaccination 
compared to adults. 
Last but not least, we used PBMCs from children receiving LAIV to assess the 
vaccine autologous A/H1N1Cal09 specific T-cell responses. IFN-γ ELISpot was 
performed using PBMCs with stimuli as Cal09 peptide pools consisting of CD4 
epitopes from HA, NA, M1, NP and PB2 proteins, and CD8 epitopes from M1, NA, 
PA and NS2 proteins. LAIV significantly induced A/H1N1Cal09 specific CD4 T-cell 
responses revealed by the elevated IFN-γ+ spot forming unit per 106 PBMCs in 
children, but no increase in CD8 T-cell responses was observed. 
Paper III (Ready to submit to The Journal of Infectious Disease) 
We demonstrated that LAIV elicited antibody responses to H3HA head and H1HA 
stalk (paper I) in children. In addition, LAIV also induced NA specific and ADCC 
antibody, as well as CD4 T-cell responses in children up to 1 year after LAIV 
vaccination. In paper III, we aimed to study the early kinetics of local and systemic, 
humoral and cellular immune responses after LAIV in children, using plasma, 
TMNCs and PBMCs from vaccinees during tonsillectomy and samples from 
unvaccinated age-matched control individuals for comparison, with HI, IFN-γ 
ELISpot and Multiplex cytokine quantification assays. 
Early kinetics of systemic antibody response were measured using plasma samples 
from the day of tonsillectomy, i.e. 3, 7 and 14 days, together with 28 and 56 days 
after LAIV with HI assay. In agreement with HI results in paper I, LAIV elicited 
significant HA specific antibody responses against H3, but not H1 at day 28. In fact, 
most of individuals had increased H3 specific antibody titre at day 14. Notably, 
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significant increases in B virus specific antibody titres were found as early as day 14, 
as well as day 28 and 56. 
Next, we measured the local and systemic T-cell responses towards homologous 
vaccine strains using TMNCs and PBMCs with H1, H3 and B split antigens as 
stimuli in IFN-γ ELISpot assay. Locally, LAIV elicited T-cell responses against H3 
and B viruses at day 14, but not against H1 virus. Systemically, LAIV induced T-cell 
responses against H1 and B viruses at day 14, but not against H3 virus. In addition, 
TMNCs and PBMCs were stimulated with H1, H3 and B split antigens pooled 
together, and cytokines (Th1, Th2 and Th17, GM-CSF) were quantified in the 
supernatants by Multiplex cytokine quantification assay. Significantly elevated 
amounts of cytokines, including IL-2, IFN-γ, IL-13 and GM-CSF were secreted from 
TMNCs 14 days after LAIV to the mixture of H1, H3 and B split antigens. No 
increase of cytokines from PBMCs was found, probably due to the limited amount of 
cells available. 
Lastly, the breadth of LAIV induced local and systemic T-cell responses were 
assessed using TMNCs and PBMCs with conserved peptide pools covering CD4 and 
CD8 epitopes as stimuli in IFN-γ ELISpot assay. In agreement with the results from 
IFN-γ ELISpot assay using A/H1N1Cal09 split antigen as stimulus, no increases of 
IFN-γ+ spot forming unit per 106 cells was observed against both CD4 and CD8 
specific A/H1N1Cal09 epitopes in TMNCs (local). Interestingly, increases of IFN-γ+ 
spot forming unit was found against the conserved CD4 and CD8 epitopes in TMNCs 
(local), although due to the limited amount of PBMCs available, no systemic T-cell 








Influenza virus causes the respiratory illness, “the flu”, with severe illness, 
hospitalization and death occurring in all age groups [246, 247]. The World Health 
Organization (WHO) identifies the elderly, young children, pregnant women and 
people with chronic medical conditions as high-risk groups (See the table 1). 
Annually, 20-30% of young children are infected with influenza viruses. Due to the 
long duration of virus shedding, young children, once infected, become the main 
transmitters in families and communities [248-252]. During A/H1N1 pandemic in 
2009, the attack rates were found consistently higher among children as compared to 
adults [253]. Studies have proven that mass vaccination of pre-school and school 
children provides herd immunity in communities, which greatly reduces virus 
transmission and indirect protection for the elderly [254-258]. 
Vaccines are a cost-effective prophylactic measure to combat influenza virus and 
influenza virus related illness in the general public, especially high-risk groups [259, 
260]. Current licensed influenza seasonal vaccines are available as inactivated, live 
attenuated, and recombinant-HA vaccines. The recombinant-HA vaccines were 
recently licensed for use in adults aged 18 to 49 years old in the US [261, 262], to 
provide an alternative for individuals allergic to eggs. For children and the majority 
of adults, the inactivated influenza vaccine (IIV) and the live attenuated influenza 
vaccine (LAIV) are the two main options available on the market. 
LAIV recommendation and application in children 
The cold-adapted, temperature-sensitive LAIV viruses replicate in the upper 
respiratory tract to mimic natural infection. Hence, LAIV induces broader and 
multifaceted immune responses including antibodies in both the blood and the upper 
airway mucosa [263] and T-cells, especially in children [264, 265] compared to IIV 
which mainly induces vaccine strain specific systemic antibody responses. In a meta-
analysis comparing systemic vaccine reactions, local and systemic antibody response, 
and vaccine efficacy between LAIV and IIV, Beyer et al. studied 18 randomized 
comparative clinical trials and demonstrated that LAIV induced significantly lower 
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levels of serum HI antibodies and significantly higher levels of local IgA antibodies 
than IIV. However, no significant difference was found between LAIV and IIV when 
assessing clinical efficacy [266]. Ambrose et al. summarized studies directly 
comparing the efficacy of LAIV and IIV in children and adults: in children 6 months 
to 18 years old, LAIV was more protective; in individuals 17-49 years old, IIV is 
similarly or more efficacious compared to LAIV, however LAIV provides greater 
against mismatched A/H3N2 strain. In older adults above 60 years old, limited data 
suggest LAIV and IIV are similarly effective [137]. In addition, Nichol et al. reported 
lower frequencies of influenza infection by a mismatched influenza virus strain in 
adults vaccinated with LAIV in a randomized controlled trial [267]. In children, 
LAIV demonstrated better cross-protection against mismatched strains [89, 139, 268, 
269]. 
LAIV vaccine has been recommended for healthy children from 2 to 17 years old in 
the UK since 2012, under the terms of a universal childhood influenza program 
following the recommendation of the Joint Committee on Vaccination and 
Immunization [270]. The direct and indirect impact of vaccination has been studied, 
where reduced influenza incidence rates were reported in adults [271] but direct 
effect in children of 4-11 years old group. In areas where children were vaccinated, 
influenza activity was consistently low and the indirect cost effectiveness of the 
program was observed [272, 273]. Interestingly, limited transmission and virus 
spreading were strongly associated with vaccination [274]. During the season 
2014/15, moderate LAIV effectiveness was reported against the circulating A/H3N2 
and drifted B strain [275]. The following season was dominated by influenza 
A/H1N1pdm09 but reduced influenza infection was observed among the vaccinated 
school-age children [276]. The A/H1N1pdm09 was from the new genetic subgroup 
(6B.1 and 6B.2) during this season and thus LAIV vaccine effectiveness was reported 
against a mismatched strain [277]. Since then, the UK continuously monitors the 
uptake and impact of the LAIV program in school children [278]. Finland introduced 
the LAIV in their national vaccination program from the influenza season 2015/16 for 
children 24 to 35 months old and they found LAIV effectively combated laboratory-
confirmed influenza. Thereafter, Finland also recommended LAIV as an alternative 
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prophylaxis to inactivated vaccine in children [279]. Interestingly, the USA 
suspended LAIV vaccine based on the report of the US Centers for Disease Control 
and Prevention (CDC), where no significance evidence of vaccine effectiveness was 
found against A/H1N1pdm09 at the end of 2015/16 season [280]. Potentially due to a 
mutation in HA that led the thermal instability of the A/H1N1pdm09 LAIV vaccine 
strain used in 2009-2014, reported by Caspard H et al. [281]. The US Advisory 
Committee on Immunization Practice therefore temporarily withdrew the 
recommendation of LAIV for the 2016/17 and 2017/18 seasons. In Norway, LAIV is 
also recommended for high-risk children between 2-17 years old with underlying 
medical conditions, but the vaccine is not regularly used [282]. 
To better understand the early kinetics as well as the longevity of LAIV induced 
humoral and cellular immune responses, we conducted a clinical trial of LAIV in 
children in the season 2012-13 and season 2013-14 in both children and adults. 
Individuals were intranasally vaccinated 3, 7 or 14 days before scheduled elective 
tonsillectomy with seasonal trivalent LAIV. Plasma and peripheral blood 
mononuclear cells (PBMCs), and saliva were collected before and up to 1 year after 
vaccination, as well as on the day of tonsillectomy. Tonsils were collected and 
TMNCs were isolated on the day of tonsillectomy from children and adults. Antibody 
responses were measured using plasma samples with a panel of standard and newly 
established assays. Systemic and local T-cell responses were characterized using 
PBMCs and TMNCs, respectively, with IFN-γ ELISpot assay and multiplex cytokine 
measurement. 
Systemic humoral immune responses after LAIV 
Neutralizing antibodies prevent influenza virus entry into host cells, and the initial 
establishment of infection. Therefore, the ability of a vaccine to elicit protective 
neutralizing antibodies has been the gold standard measurement of a successful 
vaccine. The HI assay measures HA receptor binding site specific antibodies, and an 
HI titre of 40 has been widely used as a surrogate correlate of protection in influenza 
vaccine studies, based on its correlation with a 50% reduction in the risk of 
contracting influenza in healthy adults [283]. The MN assay directly measures 
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antibody inhibiting virus entry and MN titres consistently correlated with HI titres. 
Therefore, we assessed whether LAIV elicited neutralizing antibody responses 
against homologous strains using HI (papers I and III) and MN (paper II) assays. 
LAIV elicited significant increase in neutralizing antibodies against H3 and B, but 
not the H1 virus in children. 
Sasaki et al. reported that LAIV induced cross-reactive plasmablast response towards 
HAs of heterovarient H1N1 strains [157]. We measured the cross-reactive antibody 
responses against H1, H3, H5 and H7 HAs in ELISA. We detected significant 
increase in H3 and H7, but not H1 or H5, specific antibodies [206]. All 18 serotypes 
of HAs found in influenza A viruses can be divided into two groups, largely attribute 
to the relative conserved stalk region, and H1 and H5 are both in group I, while H3 
and H7 are in group II. Therefore, we further dissected antibodies into HA head or 
stalk specific, and found LAIV elicited significant increase in H3 head specific 
antibodies and a slight increasing trend in H1 stalk specific antibodies in children 
(paper I). In addition, VN assay with a re-assortant virus cH9/1N3 also revealed a 
slightly elevated level of H1 stalk antibodies after LAIV (paper III).  
Recently, functional non-neutralizing antibodies’ contribution to shortening viral 
shedding and reduced disease severity has been more and more appreciated. With 
ELLA and ADCC reporter assays, we demonstrated that LAIV elicited significant 
increases in N1NA inhibiting antibodies and H1N1 specific ADCC antibody increase 
in children.  
HA stalk specific neutralizing antibodies can provide cross-protection by inhibiting a 
variety of viruses heterologous to vaccine strain from entering host cells. For 
example, avian influenza H5N1 and H7N1/H7N9 viruses have caused zoonotic 
outbreaks and sporadic infection in humans, which give rise to potential pandemic 
threats. The zoonotic H5 and H1 from LAIV A/H1N1pdm09 strain have divergent 
head domains but share similar stalk, as do the avian H7 and H3 from LAIV H3N2 
strain. Therefore, LAIV elicits cross-reactive antibodies, which may provide (partial) 
protection in case of H5 or H7 pandemics. Non-neutralizing HA stalk specific 
antibodies can be involved in NK cells activation and complement dependent 
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cytotoxicity of infected cells. Our observations imply that LAIV may be used to 
induce stalk based antibodies, although further studies will be required to know if 
these functional antibodies play a role in protection against H1N1. NA enables the 
cleavage of HA-sialic acid binding on infected host cells during progeny virion 
release and virus penetration through mucosal lumen. As a result, NA inhibiting 
antibodies play important roles in preventing initial establishment of infection and 
shortening virus shedding. Monto et al. reported NA inhibiting antibody titres with no 
correlation to neutralizing antibody titres measured in HI or MN assays, and therefore 
were an independent correlate of protection in their clinical trial [284]. Currently 
there’s no standard concentration of NA content in IIV although it should be present, 
but since LAIV has live viruses, its NA protein content is in a more or less consistent 
ratio to HA protein, which elicits NA inhibiting antibody responses after LAIV, often 
better than that after IIV. Although the quadrivalent LAIV monitoring study in UK 
shows no boost in NAI antibodies, but that could be due to the incompetent 
replication ability of the H1N1 vaccine strain, especially in competition with two B 
viruses [285, 286]. However, due to the tight conformational structure among HAs 
and NAs on the virus membrane, HA specific antibodies and NA specific antibodies 
may compete with each other for conformational close epitope binding [287-289]. He 
et al. demonstrated that antibody specificity profoundly influences the induction of 
ADCC, and the interaction among antibodies binding to discrete epitopes on the same 
antigen can influence the induction of Fc-dependent effector functions [51]. 
Local humoral immune responses after LAIV 
In the work included in this thesis, no local humoral immune response after LAIV 
was assessed. However, an early study from colleagues analysing the samples from 
our LAIV clinical trial showed LAIV induced significant local antibody (salivary 
IgA) responses against H3N2 and B viruses as early as 14 days after vaccination. 
Influenza specific salivary IgA levels correlated with systemic neutralizing antibody 
levels measured in HI assay. Notably, LAIV augmented influenza specific antibody 
secreting cells and local memory B-cell responses in tonsils. Local and systemic 
memory B-cell responses detected in TMNCs and PBMCs, respectively, correlated 
with each other [264].  
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Due to its route of administration, LAIV elicits more predominantly local IgA 
responses, instead of systemic IgG responses [290, 291]. An early study showed that 
the immunocompetent cells in the nasal mucosa can spread widely to the distant 
mucosal site, like salivary glands and could also potentially mediate the effective 
immunity in tonsils [292]. Belshe et al. and Ambrose et al. also reported LAIV 
elicited local IgA responses in nasal mucosa, which correlated with protection [162, 
263]. Therefore, although HI titre of 40 is used as a surrogate correlate of protection 
in influenza IIV studies [293], a different parameter, or more likely a set of 
parameters, is needed as correlates of protection to better understand the 
immunogenicity and efficacy of LAIV [294]. 
Cellular immune responses after LAIV 
CD4 and CD8 T-cell responses have been demonstrated in association with shortened 
viral shedding and reduced disease severity, in the absence of neutralizing antibodies. 
In human studies, sero-negative adults showed reduced viral shedding in response to 
the increased CD8 T-cells [295, 296]. Increased CD8 T-cells mediate the cytotoxic 
destruction of infected cells. Sridhar et al. reported that in the absence of the 
A/H1N1pdm09 specific antibody, pre-existing late-effector and cytotoxic CD8 IFN-γ 
T-cells were potentially associated with milder symptoms and less severe illness [95]. 
Wang et al. demonstrated that CD8 T-cell responses were associated with recovery 
from severe H7N9 disease [96]. However, Wilkinson et al. in a human challenge 
study showed that pre-existing CD4 T-cells correlate with lower virus shedding and 
less severe influenza symptoms in sero-negative individuals [94]. 
T-cell receptors recognize antigen epitopes presented on MHC molecules. As a result, 
T-cell epitopes are in linear structure of peptides 9-11 aa (CD8 T-cells) and 13-25 aa 
(CD4 T-cells), often much simpler than the conformational structure of B-cell 
epitopes. In addition, CD4 and CD8 T-cell epitopes can be found not only on the 
heavily divergent surface glycoprotein HA and NA, but also, perhaps more 
predominantly, on relatively conserved internal proteins, such as PB1, NP and M1. 
Consequently, CD4 and CD8 T-cell responses are more cross-reactive against a 
variety of heterologous influenza strains compared to antibody responses, which is 
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often influenza strain specific with little cross-reactivity. CD8 T-cells differentiate 
into cytotoxic T-lymphocytes (CTL), and kill virus infected host cells through 
cytokines and other effector molecules. On the other hand, different lineages of CD4 
helper T-cells can be characterized based on their distinctive cytokine secretion upon 
antigen stimulation. Th1 cells, secreting IFN-γ, IL-2 and TNFα, are involved in 
assisting anti-viral CTL responses; Th2 cells, secreting IL-4, IL-5 and IL-13, can 
promote B-cell responses; Th17 and regulatory T-cells are involved in regulating 
cellular immunity; follicular T-helper cells, secreting IL-21, mainly provide vital help 
in B-cell survival, programming and maturation within germinal centres inside 
secondary lymph nodes [49]. 
Earlier studies from colleagues using samples from the same LAIV clinical trial 
provided key knowledge in understanding cellular immune responses in children after 
LAIV. Firstly, the breadth of T-cell responses after LAIV was tested with two 
heterologous influenza viruses, A/Solomon Islands/2006 (H1N1) as a historical strain 
circulated before most of the children in LAIV clinical trial were born, and 
A/Switzerland/2013 (H3N2) as a future strain circulated after the LAIV clinical trial 
was performed. Interestingly, increases in Sol/06 specific IFN-γ+ and IFN-γ+IL2+ T-
cells, and increases in Swi/13 specific IFN γ+, IL 2+ and IFN-γ+IL2+ T-cells were 
found after LAIV. As most of the children had little chance of experiencing either of 
Sol/06 or Swi/13 virus before the LAIV clinical trial, we showed that LAIV elicited 
broadly reactive T-cell responses against both H1N1 and H3N2 viruses. Next, CD8 
T-cell responses were detected using synthetic influenza specific major 
histocompatibility complex class 1 (MHC-I) restricted peptide pools covering 
influenza internal proteins PB1, NP and M1. CD8 T-cell responses were highest to 
NP, and lower to PB1 and M1. NP-specific CD8 cells increased after LAIV and 
maintained above the pre-vaccination level up to 1 year. When the NP response were 
further dissected by age, children ≥10 years old showed significantly higher levels of 
anti-NP CD8 T-cells than those <10 years old [265]. 
In this thesis, we analysed influenza specific local and systemic cellular immune 
responses in TMNCs and PBMCs, respectively, using IFN-γ ELISpot assay with 
LAIV split antigens or peptides as stimuli (paper II and III). Additionally, we 
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measured the cytokine secretion from TMNCs and PBMCs upon LAIV split antigen 
stimulation to further dissect Th1, Th2 and Th17 responses after LAIV in children 
(paper III). We showed that LAIV elicited significant local T-cell responses against 
H3 and B viruses at day 14, but not against H1 virus. Systemically, LAIV induced T-
cell responses against H1 and B viruses at day 14, but not against H3 virus. 
Furthermore, significantly elevated amounts of Th1 and Th2 cytokines were secreted 
from TMNCs 14 days after LAIV. No noticeable increase of cytokines from PBMCs 
was found, probably due to the limited amount of cells available. Lastly, we assessed 
the breadth of LAIV induced local and systemic T-cell responses using TMNCs and 
PBMCs with conserved peptide pools covering CD4 and CD8 epitopes. Importantly, 
LAIV elicited increases of IFN-γ+ cells was against the conserved CD4 and CD8 
epitopes in TMNCs (local). 
Pre-existing immunity impacts LAIV immunogenicity 
Natural infection with influenza viruses occurs in all age groups and triggers 
multifaceted immune responses. The WHO recommends annual vaccination to 
combat seasonal influenza, especially in high-risk groups. Due to the proof-reading 
lacking replication mechanism and vast virus reservoir in migrating aqua and 
seashore birds, influenza viruses evolve constantly. As a result, immunity gained 
from last season (from vaccine or natural infection) would not necessarily be 
protective in the next season, especially in case of influenza antigenic drift and shift. 
How the pre-existing immunity from last season impacts the immune responses in the 
next season vaccination and/or infection has been the focus of more and more studies, 
but underlying mechanisms are still largely unknown. 
LAIV mimics natural infection and elicits humoral and cellular immune responses, in 
which the attenuated virus replication in upper respiratory tract is essential. 
Therefore, the influence from pre-existing immunity, especially in nasal mucosa, is 
more profound on LAIV compared to the influence on IIV [156]. Studies have proven 
that LAIV induces better immune responses and is more efficacious in children, who 
had lower pre-existing immunity, compared to adults [297]. In addition, LAIV works 
better as priming vaccine in children with no previous virus/vaccine exposure, while 
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IIV works ideally as boost vaccine in children with LAIV and/or natural infection 
history [110]. 
To better understand how pre-existing immunity impacts on LAIV immunogenicity, 
we conduced LAIV clinical trial on both children and adults, despite that LAIV is 
only recommended for children 2-17 years old in Europe.  Firstly, children had higher 
titre of neutralizing antibodies (paper I), as well as NA inhibiting antibodies against 
H1N1 virus than adults (paper II). More interestingly, children and adults who had 
received earlier pandemic or seasonal vaccine(s) had higher pre-existing H1N1 
specific neutralizing antibody titres than those had not (paper II). On the contrary, 
adults had higher amount of antibodies cross-reactive to H5 and H7 full length HA, 
H1 and H3 stalk specific antibodies (paper I), as well as ADCC antibodies (paper II). 
Here, we speculate that this intriguingly opposite pattern between children and adults 
among different types of antibodies attribute to the different mechanisms involved in 
inducing those antibodies. For example, stalk specific and ADCC antibodies are more 
cross-reactive and can be accumulated with age and multiple exposures (vaccine or 
infection), whereas neutralizing antibodies and NA inhibiting antibodies are more 
strain specific and dependent on one successful immune system stimulation, either as 
the priming strain or potent adjuvant vaccine response. The illustrated speculation is 
described for children in Figure 11 after LAIV immunization. However, more studies 




Figure 11. Speculation of how live attenuated influenza vaccine is involved in 
A/H1N1pdm09 specific immune response in children. Pre-existing antibodies derived from 
memory B-cells may direct the post-immunization response toward different pathways; (1) 
HA stalk antibodies (IgG and VN antibodies) increased and thus ADCC antibodies may be 
elevated (2) LAIV significantly increased NAI antibodies and (3) IFN-γ secreting CD4+ T-
cells were boosted after LAIV. 
In summary, LAIV requires replication of the vaccine viruses at the site of 
administration but is influenced by the pre-existing antibodies in children and adults. 
We explained the H1N1 vaccine strain in LAIV might have been protected children 
through NAI and T cellular response. Local protection is mediated by both humoral 
and cellular responses following LAIV immunization, where tonsils play a critical 
role. The systemic antibody response is broad comprising of both neutralizing and 
non-neutralizing antibodies following LAIV. A/H1N1pdm09 virus specific humoral 
immunity was not boosted in general although NAI antibody responses were elevated 
in children. Thus, NAI assay appears to be a sensitive tool to detect antibody 
responses after LAIV, where pre-existing HA specific response may not be boosted. 
Also, CD4 T-cells responses in blood were induced against A/H1N1pdm09 vaccine 
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strain. In contrast to the observation in USA, our overall study results showed LAIV 
boosted immune responses and confirm the European effectiveness data from UK and 
Finland [277, 279]. There is a multifaceted immune responses following LAIV 
immunization, which supports the continued use of live attenuated influenza vaccine 
in children. 
Limitations of the studies 
The studies included in this thesis are part of the clinical trial on trivalent LAIV in 
children and adults. As a result, our studies inherit limitations of human clinical trial, 
especially in paediatric population. The number of subjects included and samples 
collected in the studies are limited by the time and capacity of the facilities involved 
in the clinical trial. In Norway, participants including parents of children enrolled are 
not compensated. Blood sampling time points and volumes are restricted especially in 
children. As a result, immunological assays must be prioritized, if samples were not 
enough for every assay desired. Serology assays are performed with cyro-preserved 
plasma samples. Cellular assays, on the contrary, had to be performed with freshly 
isolated cells to ensure the optimal sensitivity. Therefore, we chose IFN-γ ELISpot 
assay and multiplex cytokine quantification, which are relatively short and 
straightforward. However, more in-depth analyses of cellular immune responses were 


















This PhD project aimed to understand the systemic and local immune responses in 
children and adults recruited into the LAIV clinical trial. We have gained new 
knowledge of the immunological responses after LAIV, particularly the antibodies 
including functional antibody responses to HA and NA, non-neutralizing ADCC 
responses as well as the T cellular responses, which will guide future studies of 
LAIV. In conclusion, the study has answered our primary aim of investigating the 
magnitude, quality, breadth and duration of the humoral immune response. The 
secondary objectives were met as followed as summarized below- 
Paper I provided the following knowledge- 
• LAIV elicited H3N2 specific HI antibodies in children, but in adults antibodies 
were not boosted to H3N2 or H1N1 strains and remained below the protective 
titre both pre- and post-vaccination.  
• Intranasal LAIV boosted the H3 specific IgG responses against the full-length 
and head of HA in children, but not adults. H1 specific IgG antibody responses 
were also more HA head oriented in children. Although the H3 head specific 
IgG was dominant in adults, the H1 antibodies were stalk dominant, but LAIV 
immunization did not boost head or stalk responses.  
• Importantly, we observed a trend of boosting of H1 stalk specific IgG 
antibodies in children after LAIV. Adults had higher levels of pre-existing 
stalk antibodies (towards both H3 and H1), but these were not boosted. 
• Heterologous IgG antibody responses to H5 and H7 were not boosted in either 
children or adults after LAIV immunization, although children had no H7 
cross-reactive antibodies.  
In paper II, we further investigated the H1N1 specific neutralizing and non-
neutralizing functional antibody responses and found- 
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• No significant changes were observed for micro-neutralizing (MN) antibodies 
in either children or adults after LAIV3.  
• H1 stalk specific neutralizing antibody titres were high in adults and increased 
post-LAIV vaccination in children.  
• We observed that LAIV boosted neuraminidase inhibition antibodies (NAI) in 
children, although both children and adults demonstrated NAI titres below the 
recently published protective level of NAI titre <40 [230].  
• Higher ADCC antibody titres were seen in adults compared to children pre- 
and post-vaccination against A/H1N1pdm09. LAIV immunization did not 
induce ADCC activity in either children or adults. 
• Only H1N1 specific CD4 T-cells are boosted after immunization, with almost 
undetectable CD8 T-cell responses found in children.  
 
We answered in Paper III the following- 
• Children had increases in IFN-γ responses to the influenza A virus as well as 
the conserved CD4+ and CD8+ peptides covering conserved epitopes of 
isolated influenza A viruses circulating between 1934-2009 after LAIV.  
• H1N1 specific IFN-γ response increased significantly at 56 days post-
vaccination in PBMC compared to pre-vaccination and non-vaccinated 
controls but no increase was observed in the TMNC.  
• Influenza B strain specific IFN-γ responses increased both locally (TMNC) 
and systemically (PBMC).  
• LAIV vaccination increased local and systemic IFN-γ responses for H3N2, 




• Interestingly, we showed an increasing trend of broadly cross reactive CD4+ 
T-cells, although not significant. LAIV resulted in a significant increase in 
CD8+ T-cell responses post-vaccination in the tonsils.  
• We showed the increased cytokine responses in TMNC within 14 days of 
LAIV post-vaccination demonstrated by Th1, Th2 and GM-CSF 
subpopulation and compared to control tonsils. Whereas no increase in 
cytokine responses was observed in PBMC after LAIV and confirming the 







8 Future Perspective 
This thesis utilised the LAIV vaccine trial in children aged between 3 to 17 years old 
and adults to dissect and compare the humoral immune responses. Functional 
antibodies were measured in both terms of neutralizing and non-neutralizing 
antibodies responses. The work was extended to investigate the local or systemic 
cellular immune response following LAIV administration.  
Due to time limitation, we have not studied functional or non-neutralizing antibodies 
against the H3N2 and B influenza strains in children and adults. We have shown that 
LAIV boosted IgG responses in children in blood against H3N2. LAIV boosts T-cell 
response both locally and systemically against influenza B in children. Therefore, in 
future studies we will investigate the functionality as well as the non-neutralizing 
antibodies against H3N2 and B strain in children and adults. Influenza NA antibodies 
may provide protection and could also be an important parameter for future studies of 
LAIV extending to the H3N2 and B influenza strains. Importantly, influenza NA 
functional antibodies can be analysed by the plaque reduction assay, which is more 
sensitive than MN assay, allowing the roles of neutralizing antibody to HA and NA to 
be dissected. 
LAIV is administered intranasally and the tonsils are the local draining lymph nodes. 
They are compartmentalized organs where germinal centres (GC) are formed for 
generation of high affinity antibodies and long-lived plasma cells and memory B-
cells. Follicular T-helper (TFH) cells are a subgroup of CD4+ T-cells that help B-cells 
through proliferation and affinity maturation inside GC. For future studies it will be 
important to measure mucosal antibodies and the T follicular cellular response in the 
tonsils both using flow cytometry and immunohistochemistry.  
LAIV may play a role in reducing the influenza related illness through induction of 
herd immunity in the population when vaccination rates are high enough [256]. 
Finally, as LAIV rapidly induces T-cell responses in the tonsil, we may address the 
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a b s t r a c t
Influenza is a major respiratory pathogen and vaccination is the main method of prophylaxis. In 2012, the
trivalent live attenuated influenza vaccine (LAIV3) was licensed in Europe for use in children. Vaccine-
induced antibodies directed against the main viral surface glycoprotein, haemagglutinin (HA), play an
important role in virus neutralization through different mechanism. The objective of this study was to
dissect the HA specific antibody responses induced after LAIV3 immunization to the influenza A viruses
in children and adults.
Plasma was collected from 20 children and 20 adults pre- and post-LAIV3 vaccination (up to a year) and
analysed by the haemagglutination inhibition (HI) and ELISA assays. We found that LAIV3 boosted the HA
specific IgG response against the head and the full-length of H3N2 in children, but not adults. Adults had
higher levels of pre-existing stalk antibodies (towards H3N2 and H1N1), but these were not boosted by
LAIV3. Importantly, we observed a trend in boosting of H1N1 HA stalk specific antibodies in children after
LAIV3. Whereas, heterosubtypic H5 and H7 full-length HA specific antibodies were not boosted in either
children or adults. In conclusion, LAIV3 elicited H3-head and low levels of H1 stalk specific antibody
responses in children, supporting the prophylactic use of LAIV in children.
! 2017 Elsevier Ltd. All rights reserved.
1. Introduction
Influenza viruses cause annual seasonal outbreaks or epidemics,
with occasional pandemics occurring at unpredictable intervals.
Influenza infects all age groups, although the burden of hospital-
ization is highest in very young children and the elderly [1–3].
Vaccination is the main method of influenza prophylaxis with
either inactivated influenza vaccine (IIV) or live attenuated influ-
enza vaccine (LAIV). Although used in Russia for decades, the LAIV
was first licensed in the USA in 2003 for children and adults
(2–49 years old), and in 2012 in Europe for children (2–17 years
old). LAIV is administered as a nasal spray and replicates in the
upper respiratory tract, mimicking natural infection and inducing
both humoral and cellular immune responses [4]. Trivalent LAIV
(LAIV3) has been reported to have a higher efficacy in young
children than intramuscular IIV and thus provide greater protec-
tion against influenza-associated severe complications [5–8].
Importantly, the immune response after seasonal IIV is strain-
specific, whereas LAIV3 provides better protection against mis-
matched strains [8,9].
The haemagglutinin is the major viral surface antigen, consist-
ing of two domains; the globular head and the stalk domains, with
a disulphide bride between C52 and C277 (H3 numbering) being
the demarcation line between the two domains [10]. The
immuno-dominant globular head contains the receptor-binding
site and the antigenic sites, which undergo continuous antigenic
drift. The membrane proximal HA stalk is highly conserved and
contains a conformation-dependent fusion-peptide [11]. Antibod-
ies directed against the stalk are broadly neutralizing, recognizing
divergent and heterosubtypic strains from either group 1 (includ-
ing H1 and H5) or group 2 (including H3 and H7) viruses [12–14]
and provide in vivo protection from viral challenge in animal mod-
els [14,15]. Antibodies can be boosted to the more conserved but
less immunogenic stalk, when a virus has a highly divergent HA
http://dx.doi.org/10.1016/j.vaccine.2017.08.044
0264-410X/! 2017 Elsevier Ltd. All rights reserved.
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head from a previously circulating strain, such as the 2009 pan-
demic or avian H5N1 virus [13,14,16]. Therefore, the conserved
HA stalk is a promising target for development of a future universal
influenza vaccine.
Conventional IIVs predominantly induce strain-specific antibody
to the HA head, but the type of HA response LAIV3 elicits is yet to be
fully defined. In this study, we dissected the HA head and stalk-
specific antibody responses to the homologous vaccine (H1N1 and
H3N2) and heterologous avian (H5N1 andH7N9) viruses after intra-
nasal seasonal LAIV3 vaccination in children and adults.
2. Material and methods
2.1. Participants and study design
Twenty children (3–17 years old) and 20 adults (21–59 years
old) were intranasally vaccinated (0.1 mL per nostril) with seasonal
LAIV3 (Fluenz, Astra Zeneca, Liverpool, UK). Children received one
(!9 years old, n=6) or two doses (<9 years old, n=14) of LAIV3 in
2012 at a four-week interval [4]. Adults received one dose of LAIV3
in 2013. The study had ethical and regulatory approval
(EUDRACT2012-002848-24, www.clinicaltrials.gov;
NCT01866540) and the exclusion criteria are published [4]. Plasma
was collected at 0 (pre-vaccination), 28, 56, 180 and 360 days post-
vaccination, aliquoted and stored at "80 "C.
2.2. Vaccine
LAIV3 (Fluenz) contained 107 fluorescent focus units (FFU) of
A/California/7/2009(H1N1)pdm09-like and A/Victoria/361/2011
(H3N2)-like strains in both seasons, with either B/
Wisconsin/1/2010-like or B/Massachusetts/2/2012-like in the
2012 or 2013 seasons, respectively.
2.3. Recombinant haemagglutinin proteins
The influenza A full-length and chimeric haemagglutinin pro-
teins were prepared by using the baculovirus expression system
(Table 1) [16]. The cH6/1 contained the globular head domain from
A/mallard/Sweden/81/02 (H6N1) and the stalk domain from
A/PuertoRico/8/34 (H1N1). The cH4/3 contained the H4 globular
head domain from A/duck/Czech/1956 (H4N6) in combination
with the H3 stalk domain from A/Perth/16/09 (H3N2). The HA1
proteins were purchased from eEnzyme, USA and were used as
proxy for the head domain.
2.4. Haemagglutination inhibition (HI) assay
The HI assay was conducted using serial 2-fold dilutions of
receptor destroying enzyme (RDE, Seiken, Japan) treated plasma
(starting dilution 1:10) and 0.7% turkey blood cells, as previously
described [4].
2.5. Enzyme-linked immunosorbent assay (ELISA)
The ELISA was conducted using the full-length, head or chimeric
HAs as previously described [17]. The end-point titres were calcu-
lated using the mean of the blank plus three standard deviations
as a cut off [13].
3. Statistics
Statistical differences after vaccination were analysed using the
linear mixed model in STATA/IC 14.1 for Mac (StataCorp, USA). The
Wilcoxon test was used for the head/stalk distribution after vacci-
nation and the nonparametric Mann-Whitney test for comparing
children and adult responses in HI (GraphPad Prism# V6f for
Mac, GraphPad Software, USA). The children and adult sampling
points were also compared using paired student’s t-test and
t-test with Welch correction. P < 0.05 was considered significant.
4. Results
Twenty children (median 4.5 years old) and twenty adults
(median 33.5 years old) were immunized with seasonal LAIV3
and sequential blood samples were collected up to one year
post-vaccination (Fig. 1). Fourteen children (70%) (median age
3.8 years old) received two doses of vaccine, whilst the remaining
6 children (30%) (median age 15.5 years old) and adults received
only one dose (Table 2). Ten adults (50%) and nine children (45%)
were vaccinated in 2009 with the AS03-adjuvant pandemic H1N1
vaccine (Table 2). One child’s (5%) mother was also vaccinated
while pregnant in 2009, and only one child (5%) had previously
been vaccinated with trivalent IIV.
4.1. LAIV3 boosts H3N2 haemagglutination inhibition antibody
responses in children
We examined the plasma HI antibody response against the
influenza A H1N1 and H3N2 vaccine strains after LAIV3. An HI titre
of !40 is considered to protect 50% of individuals from disease.
Pre-vaccination, fifteen children (75%) had protective antibody
titres against H1N1 (Fig.2A), which were not boosted after vaccina-
tion. Five children (25%) remained below the protective HI thresh-
old after the first vaccination, of whom one responded after the
second dose (HI titre 69) and the remaining 4 children (20%) did
not respond (HI < 10) vaccination. Children had significantly higher
HI titres than adults pre- to 180 days post-vaccination. Pre-
vaccination, ten adults had HI titres below the protective threshold
of whom nine were seronegative (HI < 10). Vaccination did not
generally boost antibody titres in adults, except two adults who
responded with protective HI titres. No change in fold change in
HI titres was observed to H1N1 after LAIV3 (Fig. 2C).
For the H3N2 strain, 10 (50%) of the 20 children had a pre-
vaccination HI titre of <40, of whom 8 (40%) were seronegative
(HI titre < 10) (Fig. 2B). After the first LAIV3 dose, there was a sig-
nificant increase (P < 0.0001) in HI titres, which remained signifi-
cantly elevated above pre-vaccination levels after the second
dose (day 56) (P < 0.0001) and until day 360 (P < 0.01). Thirteen
(65%) adults had pre-vaccination antibodies below the protective
titre (HI<40) to H3N2. LAIV3 elicited protective HI titres in two
Table 1





A/California/04/09 (H1N1) Full-length H1
H1 HA1 (head
proxy)
Chimeric protein: stalk of A/PuertoRico/8/34
(H1N1), globular head from
A/mallard/Sweden/81/02 (H6N1) Stalk (cH6/1)
A/Vietnam/1203/04 (H5N1) Full-length H5
Group
2
A/Victoria/361/11 (H3N2) Full-length H3
A/Texas/50/2012 (H3N2) H3 HA1 (head
proxy)
Chimeric protein: stalk of A/Perth/16/09
(H3N2),
globular head from A/duck/Czech/1956
(H4N6)
Stalk (cH4/3)
A/Shanghai/1/13 (H7N9) Full-length H7
S. Islam et al. / Vaccine 35 (2017) 5666–5673 5667
adults (10%) post-vaccination, only one of which was maintained
above the protective titre up to 1 year. Children had significantly
higher fold changes after LAIV3 than adults, and these were main-
tained in children up to day 360 whereas low increases were
observed up to day 56 in adults (Fig. 2D). In summary, LAIV3 signif-
icantly boosted the HI response to H3N2 in children. Generally, no
H1N1-specific HI response was boosted in either children or adults.
4.2. IgG responses to full-length H3N2 were boosted in children after
LAIV3
The IgG response was measured by ELISA to the homologous
(H1 and H3) and heterologous (H5 and H7) full-length influenza
A HAs (Table 1). High pre-vaccination IgG titres to the full-length
H1 HA were detected in both the children and adults, and LAIV3
vaccination did not boost these antibodies (Fig.3A). No correlation
was observed between pre-vaccination IgG and fold-increase
28 days post-vaccination in children against H1N1 (data not
shown).
H3-specific antibodies were detectable pre-vaccination in all
adults and in the majority of children to the full-length HA,
although 5 children had low levels of antibodies (Fig. 3B). In the
children, antibody titres increased significantly (p < 0.0005) at
day 28 after LAIV3 immunization and were generally maintained
up to day 360. Children’s IgG titres were significantly higher than
adults after one dose and up to one year post-vaccination. No
changes in H3-specific antibody responses were observed in the
adults after vaccination. Pre-existing IgG antibodies specific for
H3 full-length HA significantly but inversely correlated with fold
induction in children both at day 28 (r = "0.8412, p < 0.0001) and
day 56 (r = "0.8618, p < 0.0001).
We further evaluated the heterosubtypic antibody response. H1
and H5 are both group 1 HAs and the H3 and H7 are group 2 HAs,
with a similar conserved stalk domain. We observed a trend of
higher pre- and up to 180 days post-vaccination antibody titres
against the full-length H5 HA (Fig. 3C) in adults compared to chil-
dren. The H5 antibody titres at day 360 were significantly different
(P < 0.05) from earlier time points in both adults and children. No
change in H3 stalk antibodies was observed after LAIV3 (Fig. 3D).
However, adults had significantly higher H7 HA-specific antibody
titres pre- and up to 180 days post-vaccination compared to
children.
4.3. LAIV3 boosts H3 HA head-specific responses in children
We measured the IgG antibodies to the homologous influenza A
vaccine HA heads and stalks using chimeric HAs. The H1 head-
specific antibody titres were significantly higher in children than
the adults (Fig. 4A) pre-vaccination, although the LAIV3 did not
boost these antibodies. Adults only had a slight increase in head
antibody but this decreased by day 360. Pre-vaccination, H3 head
specific antibodies were comparable between children and adults
(Fig. 4B). In children, H3 head specific antibodies increased signif-
icantly (p < 0.05) after one dose (day 28) and were maintained up
to one year post-vaccination (Fig. 4B). However, no boost in H3
head antibodies was observed after vaccination in adults. Children
had significantly higher head H3 specific antibodies after LAIV3
immunization than adults.
The stalk-specific antibody response was assessed using chi-
meric group 1 (cH6/1) and group 2 (cH4/3)) HAs containing exotic
head domains derived from avian viruses, which do not cause
human infection. For the H1 stalk, adults had significantly higher
stalk antibody titres compared to children pre-vaccination and
up to day 180 (p < 0.05). There was a trend of an increase in the
H1 stalk antibody response in children at days 28 and 56 post-
vaccination, but not in adults (Fig. 4C). Adults had significantly
higher H3 stalk-specific antibodies pre-vaccination than the chil-
dren. LAIV3 immunization did not boost H3 stalk-specific IgG in
children or adults. H3 stalk-specific antibody titres decreased sig-
nificantly (P < 0.05) in adults at days 180 and 360 compared to
pre-vaccination titres (Fig. 4D). In summary, circulating H3N2
head-specific IgG responses were boosted and low levels of H1N1
stalk-specific antibody responses were induced in children, but
not adults.
4.4. Comparative distribution of head- and stalk-specific IgG after
LAIV3
The HA specific IgG distribution was compared by calculating
the ratio of the antibodies to the head domain and the stalk domain
in children and adults. Children, who had previously been infected
or vaccinated with the H1N109pdm virus, but with limited expo-
sure history to other influenza H1s, had more H1 head-specific
Fig. 1. The study design. Children were vaccinated with 1 (n = 20) or 2 (n = 14 children, age < 9 years old) doses of LAIV, whilst adults received one dose of LAIV. Plasma
samples were collected pre (0) and at 28, 56, 180 and 360 days post vaccination. The number (n) of children and adults providing samples at each time point is shown.
Table 2
Baseline demographics of the patient cohort.
Children Adults
Number of participants (n) 20 20
Median age by year (Range) 4.5 (3–17) 33.5 (21–59)
Male/Female (% Female) 9/11 (55%) 6/14 (70%)
Single dose (%) 6 (30%) 19 (95%)
Two doses (%) 14 (70%) 1 (5%)
Pandemic vaccination in 2009 (n (%)) 9 (45%) 10 (50%)
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antibodies pre-vaccination, which decreased post-vaccination.
However, in adults who had previously experienced several natural
H1N1 infections and/or vaccination, HA stalk-specific antibody
dominance was observed (Fig. 4E). The children had significantly
higher ratio throughout the study than adults. Both children and
adults had a H3 head dominant response (Fig. 4F). An increase in
H3 head specific-antibodies after LAIV3 immunization was
observed in children, leading to a significantly higher ratio in chil-
dren than adults post-vaccination.
5. Discussion
The licensure of LAIV in Europe in 2012 expanded available pro-
phylaxis for influenza, offering an attractive easily administered
nasal spray vaccine for children. In Norway, annual seasonal influ-
enza vaccination is only recommended for high-risk populations
and thus most of our volunteers had not previously received
seasonal influenza vaccination. In this study, we dissected the
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Fig. 2. The haemagglutination inhibition (HI) antibody responses in children and adults after live attenuated influenza vaccination. HI titres were measured towards the
homologous influenza A/California/7/09 (H1N1) (A) and A/Victoria//361/11 (H3N2) (B) vaccine strains in both children and adults after live attenuated influenza vaccination.
The dotted line shows an HI titre of 40, considered the protective level. The fold increase in children from pre-vaccination antibody titres to H1N1 (C), and H3N2 (D)
homologous viruses. Ratios above or below 1 indicate higher or lower post-vaccination HI titres compared to pre-vaccination titres, respectively. Blood was collected at 0
(pre), 28 (after 1st dose), 56 (after 2nd dose in children < 10 years old), 180 and 360 days post vaccination. Each circle represents the HI response of one individual with the bar
showing the group geometric mean HI titres ± 95% confidence interval. Open circles are children while filled circles are adults.. The nonparametric Mann-Whitney test was
used to investigate statistical significance between children and adults. The linear mixed model was also used to investigate the change from pre-vaccination antibody titres
up to one year for both children and adults; *p < 0.05.
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intranasal LAIV3 vaccination in children and adults. Our results
show that LAIV3 boosted the H3-specific antibody responses in
children, but not adults, and the antibody response was dominated
by antibodies to the HA head domain. A trend of increase in H1
stalk specific antibodies was found in children after LAIV3. Adults
who have previously experienced repeated influenza infection
had higher pre-existing H1 stalk-specific antibodies, but these
were not boosted after LAIV3 immunization.
The golden standard haemagglutination inhibition (HI) assay
mainly measures neutralising HA head-specific antibodies with a
serum HI titre of 40 considered protective in adults [18]. Although
in children HI titres of 110 have been proposed as providing 50%
protection to H3N2 after IIV vaccination [19]. We found that
LAIV3 only boosted H3N2 HI antibodies (>110) in the children,
and these titres were maintained up to a year. Generally, no boost
in the HI antibody was observed to the H1N1pdm09 virus in either
adults or children, in agreement with our previous findings in
children [4]. Pre-existing influenza-specific antibodies, particularly
to H1N1pdm09 from previous infection or vaccination, may
limit replication of the H1N1pdm09 LAIV strain and therefore
restrict stimulation of the immune response [20], but should also
provide protection against H1N1pdm09 infection. Interestingly,
studies in the USA have shown reduced vaccine effectiveness
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Fig. 3. The haemagglutinin specific antibody response to seasonal and heterosubtypic influenza A viruses. The IgG response to the haemagglutinin of the homologous vaccine
strains (A/California/4/2009 (H1N1) (A) and A/Victoria/361/11 (H3N2) (B)) and the avian (A/Vietnam/1203/04 (H5N1) (C) and A/Shanghai/1/13 (H7N9) (D)) viruses was
measured by ELISA. Each circle (open = children, filled = adults) represents the endpoint titre of one individual, and the bars show the geometric mean titre ± 95% confidence
interval. The sampling points were at day 0 (pre-vaccination) and days 28, 56, 180 and 360-post vaccination. The children and adult sampling points were compared using
paired student’s t-test and t-test with Welch correction. *p < 0.05.







































































































Fig. 4. The IgG HA specific response to the haemagglutinin head and stalk of influenza A H1N1 and H3N2 viruses. The head and stalk IgG responses to the HA of A/California/
4/2009 (H1N1) (A, C) and A/Victoria/361/11 (H3N2) (B, D) were measured by ELISA. The time points for sampling were day 0 (pre-vaccination) and days 28, 56, 180 and 360
post vaccination, as indicated on the x-axis. Each circle (open = children, filled = adults) represents the endpoint titre of one individual and the bars show the geometric mean
titre ± 95% confidence interval. E (A/California/4/2009 (H1N1)) and F (A/Victoria/361/11 (H3N2)) show the ratio between head and stalk antibody titres on a log2 scale, where
a ratio of 1 shows an equivalent distribution of stalk and head antibody. The bar charts indicate the mean titre ± 95% confidence interval. The children and adult sampling
points were compared using paired student’s t-test and t-test with Welch correction. *p < 0.05.
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in Europe the LAIV has been shown to be effective against labora-
tory confirmed influenza [23]. The H1Npdm09 LAIV strain used in
2009–2014 had a mutation in the HA (E47 amino acid residue) that
potentially led to reduced thermal stability of this strain [21]. As a
consequence of lower effectiveness against H1N1, the LAIV is not
recommended in the USA by the Advisory Committee on Immu-
nization Practices (ACIP) for the 2016–17 season although in Eur-
ope LAIV is still recommended. These findings of no or low
increases in H1N1-specific antibodies observed in our study may
help explain the lower effectiveness of the H1N1 strain.
We further used the HA proteins from the homologous vaccine
strains to dissect the IgG response to the immunodominant head
and the subdominant stalk domains. Our data demonstrate
increased IgG antibodies after the first dose of LAIV3 in children
to the H3 full-length protein and the H3 head, which persisted
up to one year. These head-specific antibodies, that can also be
detected by the HI assay, have higher neutralizing capacity than
stalk-specific antibodies in vitro [24]. Furthermore, our recent
study reported that the IgG1 subclass is boosted against the H3
head after LAIV3 [25]. Interestingly the full-length H3N2 HA speci-
fic IgG corresponds with the head-specific IgG titres in both groups.
The titres of stalk-specific antibodies were determined by age and/
or previous exposure history. Adults had higher pre-existing H7
specific antibodies with similar titres to the chimeric H3 stalk. In
contrast, the children had low or undetectable levels of pre-
existing H7 stalk specific antibodies illustrating the lack of group
2 influenza virus exposure [12]. Lower stalk specific antibodies to
the group 2 stalk (H3 and H7) than to group 1 stalk were detected
in children, possibly due to exposure to mostly one group 2 virus
(H3N2) during their life span.
Both children and adults had pre-existing IgG antibodies to the
head of H1, which generally did not boost upon vaccination. Higher
head specific titres were observed in children compared to adults,
reflecting recent influenza infection with an antigenically similar
virus. Interestingly, higher pre-existing stalk H1 antibodies were
observed in adults than children probably due to sequential expo-
sure to antigenically distinct HAs from group 1 (seasonal and pan-
demic H1 and H2 viruses) causing selective boosting of antibodies
to the highly-conserved stalk, similarly reviewed by Krammer et al.
[10]. The HAs of H5N1 and H1N1pdm09 viruses belong to group 1
with similar stalk, but divergent head domains. Higher levels of H5
antibody were found in adults compared to children pre- and post-
vaccination, reflecting adults more extensive previous group 1
infection history resulting in higher levels of cross reactive (heter-
subtypic) stalk antibodies. As hypothesized, the presence of a novel
globular head in the H1N1pdm09 virus skewed the antibody
response to the heterologous stalk in adults [10,26,27]. We have
earlier reported that pandemic vaccination with H5N1 vaccine
containing a highly divergent HA head and a group 1 stalk boosted
the neutralizing stalk-specific responses after the first vaccination
in adults [14].
In contrast, children have had limited influenza exposures to
group 1 HAs. In agreement, Nachbagauer et al. found that HA
stalk-reactive antibodies increased with age after repeated expo-
sure to divergent influenza viruses with conserved stalks [28].
Stalk-reactive antibodies are not extensively induced after sea-
sonal IIV [13,29–32], but we found that children with limited pre-
vious influenza infection or earlier pandemic vaccination had pre-
existing H1 stalk specific IgG that was boosted by seasonal LAIV3
vaccine, although not significantly. This may allow LAIV3 to be
used as a priming strategy for a future universal influenza stalk
based vaccine.
The continuous antigenic drift and occasional pandemics with
the associated time delay in production of pandemic vaccine high-
lights the need for development of universal influenza vaccines,
which can provide broader and longer lasting immunity. This study
shows that LAIV can boost stalk-specific antibodies in children in
the absence of a boost in head specific responses a finding, which
would need to be confirmed in a larger group of children. Nachba-
gauer et al. also showed that a high dose recombinant HA seasonal
vaccine boosted stalk-specific responses in adults 19–49 years old.
Recently, Impagliazzo et al. engineered stable trimeric stems,
which were effective at inducing broad protection in pre-clinical
animal models [33]. Stalk-specific antibodies provide broader cross
reactivity through virus neutralisation and by activation of NK cells
through FccR resulting in lysis of target cells. Further studies could
evaluate the functionality of the stalk specific antibodies in chil-
dren and adults by antibody dependent cellular cytotoxicity
(ADCC) and neutralization assays, although a recent study found
that LAIV did not induce ADCC in children [34].
In conclusions, adults had higher pre-existing H1 HA stalk anti-
bodies, whereas children had H1 head dominant antibodies proba-
bly reflecting recent infection with the same H1 strain. LAIV3
mimics natural infection in children eliciting H3N2 HA head and
low levels of stalk H1N1 antibodies, confirming LAIV as a priming
of young children.
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